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Måling av helserelatert livskvalitet og aspekter av klinisk farmakologi ved bruk av 
metadon hos pasienter med kronisk smerte som ikke skyldes kreftsykdom 
Langvarige smertetilstander som ikke skyldes kreftsykdom rammer en stor andel av 
befolkningen og fører til en betydelig reduksjon i selvrapportert helserelatert livskvalitet. 
Pasientene med de mest alvorlige og kompliserte smertetilstandene blir vurdert på 
tverrfaglige smerteklinikker. I noen tilfeller vil en del av behandlingen på en tverrfaglig 
smerteklinikk være bruk av morfin eller liknende medisiner. En andel av pasientene som får 
slike medisiner vil oppleve at de til tross for dette ikke får god nok smertelindring eller får 
for mye bivirkninger.  
Målet for denne avhandlingen var 1.) å vurdere om livskvalitets spørreskjemaet EORTC 
QLQ-C30 gir nøyaktige og pålitelige målinger av helserelatert livskvalitet hos pasienter 
som skal vurderes på en tverrfaglig smerteklinikk 2.) å sammenligne helserelatert 
livskvalitet mellom pasienter på en tverrfaglig smerteklinikk og pasienter med langtkommet 
kreftsykdom som mottar lindrende behandling 3.) å vurdere effektene av et bytte fra morfin 
til metadon hos kroniske smertepasienter med utilfredsstillende balanse mellom 
smertelindring og bivirkning under behandling med morfin.  
Data fra 288 pasienter med kroniske smerter ble samlet inn ved første konsultasjon på 
tverrfaglig smertesenter på St. Olavs Hospital. Disse dataene ble brukt til å vurdere 
nøyaktigheten og nytten av livskvalitet spørreskjemaet EORTC QLQ-C30 i denne 
pasientgruppen, og til å sammenligne livskvalitet med 434 pasienter med langtkommet 
kreftsykdom. En gruppe på tolv pasienter med utilfredsstillende balanse mellom 
smertelindring og bivirkninger under behandling med morfin for langvarige smerter byttet 
fra morfin til metadon. I oppfølgingsperioden på ni måneder ble smertelindring, 
helserelatert livskvalitet og kognitiv funksjon vurdert. Det ble også tatt blodprøver for å 
måle konsentrasjonen av morfin og metadon i blodet samt EKG for å vurdere økning i QT-
tid, som kan gi økt risiko for hjerterytmeforstyrrelser.  
Resultatene fra studiene som avhandlingen bygger på, viser at pasienter som kommer til 
behandling på tverrfaglige smerteklinikker rapporterer langt dårligere livskvalitet enn 
normalbefolkningen. På de fleste områder rapporterer de tilsvarende dårlig livskvalitet som 
pasienter som mottar lindrende behandling for langtkommet kreftsykdom. Omtrent 
halvparten av pasienter som byttet til metadon rapporterte en betydelig og langvarig 
bedring i helserelatert livskvalitet og fysisk funksjonsnivå etter byttet. Konsentrasjonen av 
metadon i blodet var stabil i de ni månedene pasientene ble fulgt opp. Det var en liten 
økning i QT-tid, men økningen var ikke stor nok til å ha klinisk betydning. 
Cand.med. Olav Magnus Søndenå Fredheim 
Institutt for Sirkulasjon og bildediagnostikk, NTNU 
Hovedveileder: Professor Petter C. Borchgrevink  
Biveiledere: Professor Stein Kaasa, professor Ola Dale og førsteamanuensis Pål Klepstad 
Finansieringskilde: Samarbeidsorganet mellom Helse Midt-Norge RHF og NTNU
Ovennevnte avhandling er funnet verdig til å 
forsvares offentlig for graden PhD i klinisk medisin 
Disputas finner sted i Auditoriet (MTA), Medisinsk teknisk senter 
torsdag 24. mai 2007, klokken 12.15 

Abstract
Introduction 
The patients with the most severe and complex chronic non-malignant pain (CNMP) 
conditions are admitted to multidisciplinary pain centres. A poor health related quality 
of life (HRQoL) has been documented in these patients but their HRQoL scores have to 
a very limited degree been compared to other patient groups. Such comparisons require 
the application of the same HRQoL instruments in different populations. While non-
pharmacological treatment is preferred in this patient group, treatment with strong 
opioids is an option for some patients. After start of opioid therapy about half the 
patients experience an unacceptable balance between side effects and pain relief. 
According to research in cancer pain, a switch to methadone may improve pain control 
in these patients. However, there are several areas of uncertainty related to this switch in 
CNMP patients. It has not been evaluated in prospective studies with long-term follow 
up and both increased QTc time (QT time adjusted for heart rate) and autoinduction of 
methadone metabolism during long term treatment have been indicated in other patient 
populations.
Research questions 
HRQoL assessment methodology in CNMP patients: 
I. Is the EORTC QLQ-C30 a valid alternative to the SF-36 for assessment of 
HRQoL in CNMP patients?  
Comparison of HRQoL scores between patient groups: 
II. How is the HRQoL of CNMP patients admitted to multidisciplinary pain centre 
treatment compared to the HRQoL of palliative cancer patients? 
Opioid switching from morphine to methadone in CNMP patients with an unacceptable 
balance between pain control and side effects during morphine therapy:
III. What are the effects on pain control, HRQoL, cognitive functioning and patient 
preference?
IV. What is the effect on QTc time? 
V. Are methadone serum concentrations stable during long term treatment and are 
there interindividual differences in opioid metabolism?  
Methods
HRQoL data were collected from 288 CNMP patients admitted to multidisciplinary pain 
treatment. These data were used for psychometric validation of the EORTC QLQ-C30 
HRQoL questionnaire and for comparison of HRQoL with palliative cancer patients.
Twelve patients with unacceptable balance between pain control and side effects during 
morphine treatment for CNMP switched to methadone. Pain, HRQoL, cognitive 
functioning, opioid serum concentrations and QTc were evaluated at baseline and one, 
two, six and 13 weeks and nine months later.   
Results
Internal consistency was below 0.70 for five of nine EORTC QLQ-C30 multi-item 
scales. Large floor or ceiling effects were seen for several scales. These weaknesses do 
not disrupt the picture of overall acceptable psychometric properties in this population.
Compared to palliative cancer patients, patients with CNMP reported poorer global 
quality of life and cognitive functioning and more pain, sleep disturbances and financial 
difficulties as well as equally poor physical, social and emotional functioning and 
equally high levels of diarrhoea, dyspnoea and fatigue. 
Seven patients preferred long-term (> nine months) treatment with methadone and 
reported reduced pain and improved functioning while cognition was not improved. On 
the other hand one patient experienced sedation requiring naloxone and four patients 
were switched back to morphine due to poor pain control, drowsiness or sweating. 
Mean increase in QTc was 0.020 seconds. Serum concentrations of methadone and its 
metabolite EDDP were stable from the end of dose titration and during the nine months. 
Conclusions
x The EORTC QLQ-C30 is a valid alternative to the SF-36 for HRQoL assessment in 
CNMP patients.
x CNMP patients admitted to multidisciplinary pain centres report as poor HRQoL as 
palliative cancer patients.
x Opioid switching to methadone causes improved pain control and HRQoL in some 
patients but is not beneficial to all patients and poses a risk of serious sedation.
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Introduction
Chronic non-malignant pain  
Epidemiology  
Pain is defined by the International Association for the Study of Pain (IASP) as “An 
unpleasant sensory and emotional experience associated with tissue damage, or 
described in terms of such damage” (IASP 1994b). The definition of chronic pain is 
less clear, but IASP has suggested that chronic pain is pain persisting beyond the 
normal time of tissue healing (IASP 1994a). The uncertainty in the definition of 
chronic non-malignant pain is reflected in the diverging inclusion criteria or case 
definitions in recent epidemiologic studies of chronic non-malignant pain (CNMP). 
While all these studies excluded patients with current malignant disease, they applied 
a pain duration of either three (Elliott et al. 1999;Blyth et al. 2001;Rustoen et al. 
2004) or six months (Eriksen et al. 2003;Breivik et al. 2006) in their case definition.  
The above mentioned differences in case definition between epidemiological studies 
probably contribute to the large variability in the prevalence estimates of CNMP in 
the population. In recent surveys from Denmark and the United Kingdom the 
prevalence of chronic non-malignant pain has been estimated to 19 and 47% 
respectively (Elliott et al. 1999;Eriksen et al. 2003). Recently a mean prevalence of 
19% was reported in a study including 16 European countries and Israel, with 
variation in prevalence from 12 to 30% across countries (Breivik et al. 2006). An 
older review of pain prevalence studies from 1984 to 1994 reported prevalence 
estimates from 2 to 40% (Verhaak et al. 1998). Besides differences in case definition, 
also differences in the wording of questions and differences in the research 
methodology may have contributed to the diverging prevalence estimates. 
Nevertheless the results from the epidemiological studies indicate that the prevalence 
differs between countries. CNMP conditions are not necessarily of life long duration. 
Annual recovery rates of 5 and 9% respectively have been estimated in two different 
studies (Elliott et al. 2002;Eriksen et al. 2004a).  
The different CNMP conditions can be sufficiently treated at different levels of the 
health care system depending on the severity and complexity of the pain condition. 
The majority of those reporting CNMP in epidemiologic surveys are not in need of 
specialised services. Patients with more serious conditions are treated by specialists 
like rheumatologists, surgeons or rehabilitation specialists, while patients with the 
most severe and complex conditions are admitted to tertiary line multidisciplinary 
pain centres (MDPCs). Overall the population reporting CNMP in epidemiological 
studies utilize nearly twice as much health care resources as the general population 
(Eriksen et al. 2004b). A high proportion is, however, dissatisfied with the 
investigations performed (33%) or with the treatment they have received (40%) 
(Eriksen et al. 2003).
Multidisciplinary treatment 
Treatment in MDPCs is required for the most severe and complex CNMP conditions 
and is reported to reduce pain and improve physical functioning, quality of sleep and 
psychological well-being (Becker et al. 2000). The treatment in MDPCs aims at 
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rehabilitation and improved functioning, but seldom complete pain relief (Ashburn 
and Staats 1999). At admission patients are seen by several professionals; usually a 
medical doctor, a physiotherapist and a psychologist. Following this first evaluation 
the multidisciplinary team decides a treatment strategy or suggests treatment to be 
followed in the primary health care. The treatment options include education about 
pain, improving coping strategies, pharmacological treatment, socio-economic 
counselling and physiotherapy/exercise. Treatment of psychological comorbidities 
like depression and anxiety is important for some patients. For a minority of CNMP 
patients opioid therapy is indicated when all other therapeutic options have been 
exhausted without obtaining adequate pain relief. Like all other treatments opioid 
therapy does not aim at complete pain relief but at improved functioning and health 
related quality of life (HRQoL) (Kalso et al. 2003). 
Assessment of health related quality of life, symptoms and 
functioning 
Introduction 
The concept of health related quality of life (HRQoL) as not only absence of disease 
is reflected in the World Health Organization (WHO) definition of health as physical, 
emotional and social well being (WHO 1946). CNMP patients often have several 
complaints and reduced functioning in addition to pain, and psychological/psychiatric 
comorbidities are common (Becker et al. 1997). Accordingly several domains of 
symptoms and functioning need to be assessed. In clinical routine a broad assessment 
is required in order to tailor the treatment strategy and to evaluate the therapeutic 
outcomes. Also in pain clinical trials it is required to assess several domains in 
addition to pain. These domains include physical, emotional and cognitive functioning 
as well as the symptoms fatigue and difficulties of sleep and socioeconomic problems 
(Turk et al. 2003).
Simple instruments for assessment of functioning such as the Barthel Index (Mahoney 
and Barthel 1965) and the Karnofsky performance scale (Karnofsky DA and 
Burchenal JH 1949) are regarded predecessors of more comprehensive HRQoL 
instruments (Fayers and Machin 2000). True HRQoL instruments developed during 
the most recent decades usually include a broad assessment of several domains of 
functioning as well as symptoms. Among the abundance of instruments an important 
dividing line is between generic instruments which are developed for use across 
patient populations and settings and the disease specific instruments. Two examples 
of common HRQoL instruments are the SF-36 and EORTC QLQ-C30 which were 
developed in the late 1980’s and introduced in the early 1990’s (Aaronson et al. 
1993;Ware, Jr. and Gandek 1998). While SF-36 is a generic instrument, the EORTC 
QLQ-C30 was developed for use in cancer clinical trials. Other frequently applied 
generic HRQoL instruments are WHOQOL (The WHO quality of life group 1998), 
the Nottingham health profile (Hunt et al. 1980;Wiklund 1990), The Sickness Impact 
Profile (Bergner et al. 1981) and the EuroQoL (Brooks 1996). In spite of the broad 
spectrum of functions and symptoms assessed by the HRQoL instruments, other 
instruments are often added for a more thorough evaluation of certain domains. For 
patients with CNMP physical, emotional and cognitive functioning and pain are 
usually subject to more thorough evaluation both in clinical routine and in research, 
and several specific assessment tools are available (Turk and Melzack 2001;Turk et 
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al. 2003;Dworkin et al. 2005). Some HRQoL instruments have optional modules 
which can be added in specific patient populations. An example of an optional module 
is the EORTC QLQ-C30 head and neck cancer module (Bjordal et al. 1994). 
Validation
Instruments for the assessment of symptoms or HRQoL need to be validated to ensure 
that they really measure what they are intended to, detect true changes over time and 
differentiate between subjects. While generic instruments are developed and validated 
for use across disease groups, the disease specific instruments are usually only 
validated in a specific population. If a disease specific HRQoL instrument shall be 
applied in any other patient population validation studies in this population is 
required. When an instrument has been translated, repeated validation is also required 
to ensure that the translated version performs as well as the original. The validation 
process includes assessment of several psychometric properties. The key 
psychometric properties are briefly described below.
Discrimination
Discrimination is an assessment of how well an instrument differentiates between 
subjects with different levels of functioning or symptom burden. When discrimination 
is high, the patients’ responses are distributed along the whole range of the response 
alternatives. In a tool with poor discrimination, a large proportion of responses will be 
one of the extreme alternatives. Discrimination is assessed by measuring the floor and 
ceiling effect, which is the percentage of responses in either end of the response 
range. Large floor or ceiling effects indicate poor discrimination.  
Responsiveness and sensitivity 
The abilities to detect true changes over time and between groups are often described 
as responsiveness and sensitivity, respectively. However, these properties are closely 
related and the terms are not consistently used in the literature.  
Responsiveness usually describes the ability to detect changes in one patient or a 
group of patients over time. When the patient experiences an improvement or 
deterioration in any domain covered by the HRQoL instrument, this experienced 
change should be reflected in an increased or reduced HRQoL score. If response 
ranges are narrow or the questions too vague changes might not be detected.  
Sensitivity is usually used to describe how well an instrument identifies differences 
between groups. An instrument with a high sensitivity is able to detect a relatively 
small difference between groups with a modest sample size. Sensitivity is assessed by 
comparing the scores of different groups of patients. Populations may be divided into 
groups according to diagnosis, performance status and so on.  
Construct validity
With the exception of global quality of life scales, each scale in a HRQoL instrument 
is supposed to assess one specific dimension of HRQoL. A physical functioning scale 
is for instance supposed to measure the construct physical functioning. Construct 
validation evaluates how well a scale measures the construct it is intended to measure. 
A simple form of construct validation is known groups validation which assesses 
whether groups expected to experience different levels of HRQoL report different 
scores. Patients who are dependent on help for their activities of daily life would for 
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instance be expected to report worse physical functioning than those who are not 
dependent on help. Another analysis strategy is assessment of convergent and 
discriminant validity. This strategy is based on the assumption that some HRQoL 
dimensions (constructs) are strongly associated while others are less strongly related. 
When testing convergent validity one assumes that scales measuring the same 
underlying or related construct have high correlation coefficients exceeding 0.40. On 
the opposite, by discriminant validity one assumes that scales measuring different 
constructs should show low correlation (<0.40). Convergent and discriminant validity 
is usually measured in a multi trait multi method (MTMM) analysis. In the MTMM 
analysis correlations between the results from different measurement methods of 
different traits (HRQoL dimensions) are presented. The construct validation may also 
include comparison of deviation from norm-data between two instruments.  
Reliability
A reliable instrument has a high degree of correlation between items in multi item 
scales. The reliability is expressed as the internal consistency which is determined by 
Cronbach’s coefficient (Cronbach’s alpha). The coefficient value reflects both the 
number of items and the degree of correlation between them. Values above 0.70 
usually indicate acceptable internal consistency and reliability.
External convergent validity
The external convergent validity is an assessment of the correlation between two 
instruments’ measures of the same concept. Such correlations should be high and the 
correlation coefficient values should exceed the values for correlations between scales 
measuring different concepts. For instance correlation between two instruments’ 
physical functioning scales should be high and substantially higher than correlation 
between physical functioning in one instrument and all other scales in the other 
instrument. The correlation coefficients required for assessment of external 
convergent validity are included in the MTMM analyses.
Health related quality of life and chronic non-malignant pain 
HRQoL in CNMP populations has been assessed using the SF-36 both in clinical 
trials (Becker et al. 2000) and epidemiological studies (Becker et al. 1997;Elliott et al. 
2002;Eriksen et al. 2003;Bergman et al. 2004). However, disease specific HRQoL 
instruments have been developed for several chronic pain conditions such as 
rheumatoid arthritis, ankylosing spondylitis and migraine (Martin et al. 2000;Russak 
et al. 2003;Doward et al. 2003) and are applied in trials in these populations. Recently 
the EORTC QLQ-C30 has also been applied at a MDPC treating CNMP conditions 
(Wincent et al. 2003).  
Studies of HRQoL in CNMP patients have demonstrated that the part of the 
population reporting chronic pain in epidemiological surveys has a statistically and 
clinically significant reduction in HRQoL compared to the general population 
(Eriksen et al. 2003). In the minority of CNMP patients admitted to MDPCs an even 
larger reduction is observed (Becker et al. 1997;Wittink et al. 2004). 
Due to use of different HRQoL instruments in different studies, it is difficult to 
compare the results both within CNMP cohorts and with other patient groups. 
Accordingly few such comparisons have been made. One study has indicated that 
patients with chronic headache experience different HRQoL from patients with 
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chronic low back pain in four of eight SF-36 scales (Gerbershagen et al. 2002) while 
patients admitted to a Danish MDPC reported  SF-36 scores in the same range as 
patients with severe cardiopulmonary disease or major depression (Becker et al. 
1997).
Comorbidities and associated symptoms in chronic non-malignant 
pain 
As mentioned above, chronic pain patients often experience additional symptoms and 
reduced functioning as well as psychiatric comorbidity. In the methadone switch 
study cognitive functioning was assessed by three neuropsychological tests while 
several other symptoms were addressed using the EORTC QLQ-C30 in both the 
methadone switch study and the two HRQoL studies. This part of the introduction 
provides a brief overview over associated symptoms and comorbidities in CNMP with 
particular focus on cognitive functioning.
Cognitive functioning
The authors of a comprehensive review of chronic pain and neuropsychological 
impairment concluded that neuropsychological impairment is frequent in CNMP, 
particularly impairment of attentional capacity, processing speed and psychomotor 
speed (Hart et al. 2000). Even though data have not been presented for pain patients, 
data from other patient populations indicate that minor impairments in cognitive 
functioning may impair functioning in work as well as activities of daily life (Rao et 
al. 1991). The mechanism for impairment of cognitive functioning in chronic pain is 
not established, but several mechanisms such as neuroplastic changes, production of 
inhibitory substances in the central nervous system (CNS) and chronic stress reactions 
with increased glucocorticoid levels have been suggested. It has also been suggested 
that pain is an attention-demanding perceptional stimulus which competes for 
attentional resources. The influence from pain on cognitive functioning does not seem 
to be determined by pain intensity and location alone. The effects could also be 
mediated through other common symptoms in pain patients such as emotional 
distress, difficulties of sleep and fatigue.
Opioids as well as other medications may also have a sedative effect. In a study of 
chronic pain patients receiving long term therapy with long acting opioids patients 
performed significantly worse than healthy controls in continuous reaction time, 
finger tapping test and the paced auditory addition test (PASAT) (Sjogren et al. 2000). 
Among the pain patients higher pain intensity was positively correlated to PASAT 
scores and indicated an arousal effect from pain on working memory. The cross 
sectional study design does not allow conclusions on whether the impairment in 
cognitive functioning was caused by the chronic pain condition or the opioid 
treatment. A more recent study from the same group compared CNMP patients 
without any pain medication to CNMP patients on long term opioid therapy with long 
acting opioids without co-analgesics, CNMP patients only receiving antidepressants 
and/or anticonvulsants and CNMP patients receiving combined treatment with opioids 
and antidepressants and/or anticonvulsants (Sjogren et al. 2005). Testing included 
continuous reaction time, finger tapping test and PASAT. The overall patient 
population performed worse than healthy controls in continuous reaction time and 
finger tapping while no significant difference was observed in performance in the 
PASAT. The subgroup analyses indicated that patients on opioid therapy performed 
poorer than patients without pain medication in the PASAT. However, due to the non-
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randomised design it can be questioned whether differences between the groups were 
caused by differences in medication or by differences in pain conditions. A quite 
recent review of effects on cognition from opioids in patients with chronic pain 
concluded that it was not determined whether the reduced cognitive functioning in 
CNMP patients on long term opioids was caused by the opioid treatment or 
confounding factors (Chapman et al. 2002). However, the available data suggested the 
greatest impairment shortly after start of opioids. A randomized controlled trial (RCT) 
of morphine for CNMP which included cognitive functioning as a secondary outcome 
found no change in cognitive functioning during morphine treatment compared to 
placebo (Moulin et al. 1996).
Other symptoms
Anxiety and depression are common comorbidities of CNMP. It is not established 
whether these conditions are part of the aetiology for development of CNMP 
conditions or reactions following the development of CNMP conditions. Hospital 
anxiety and depression scale (HADS) (Zigmond and Snaith 1983) scores from MDPC 
patient populations show mean values substantially below reference values and 
indicate a prevalence of 40% and 50% respectively for self reported depression and 
anxiety (Becker et al. 1997;Harris et al. 2003). Harris et al also reported a Beck 
Depression Inventory (BDI) mean score of 21.2 in  CNMP patients admitted to a 
MDPC (Harris et al. 2003). This corresponds to the average scores of patients with 
mild to moderate depression (Beck et al. 1961). 
Sleep disturbances are frequent among CNMP patients admitted to MDPCs. In one 
study only 12% of patients rated their quality of sleep as “good” during the last week 
before their first consultation at a MDPC while 46% reported their quality of sleep to 
be “fair” and 42% to be “poor” (Becker et al. 1997). 84% reported that their sleep was 
interrupted by pain. A review found an overall prevalence of 50 to 70% of difficulties 
of sleep in CNMP patients admitted to MDPCs (Menefee et al. 2000). It was 
speculated that pain is probably only one of several factors contributing to impaired 
sleep in this patient population. Other possible factors are psychological comorbidities 
and side effects from pharmacological treatment. 
Fatigue is a prevalent symptom in cancer patients (Stone et al. 1998). Even though 
data from CNMP patients are sparse, there are indications that also CNMP patients 
experience increased levels of fatigue compared to the general population. In one 
study patients with chronic low back pain or neck pain reported levels of fatigue close 
to the levels in a diverse group of cancer patients admitted to radiotherapy when 
fatigue was assessed with the Multidimensional Fatigue Inventory (Fishbain et al. 
2004). A recent review also reported an association between pain and fatigue in 16 of 
the 17 included high quality trials (Fishbain et al. 2003). This review concluded that 
there seems to be an aetiological relationship between pain and the development of 
fatigue. These findings are supported by poor scores in the vitality scale of the SF-36 
among CNMP patients admitted to MDPCs (Becker et al. 1997;Wittink et al. 2004).  
The pharmacological treatment of CNMP conditions poses a risk of side effects. 
Nausea/vomiting, constipation and drowsiness are common side effects of opioid 
therapy (Kalso et al. 2004). Drowsiness, dizziness and nausea/vomitting are among 
the frequent side effects of anticonvulsants while dry mouth, sweating and dizziness 
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are frequent during treatment with tricyclic antidepressants (Jensen 2002;Sindrup et 
al. 2005).
Assessment in clinical trials 
Treatment decisions should be based on evidence from clinical research. However, 
single trials may have methodological weaknesses or biases and positive results may 
be false positives. Clinical decisions and strategies should be supported by several 
trials and it is commonly agreed that the highest level of evidence for medical 
treatment is conclusions from meta-analyses or systematic reviews of RCTs (Hadorn 
et al. 1996;Harbour and Miller 2001). Meta-analyses require a certain level of 
uniformity in outcome assessment and reporting, and lack of standardisation is a 
major obstacle when information from several trials is compared or combined. The 
Initiative on Methods, Measurement and Pain Assessment in Clinical Trials 
(IMMPACT) aims at introducing a standard for outcome assessment and reporting in 
pain clinical trials. The IMMPACT group first identified the core outcome domains 
for pain clinical trials (Turk et al. 2003) and have later published recommendations 
concerning the choice of outcome measures and instruments (Dworkin et al. 2005). 
The recommendations from the IMMPACT group are summarised in table 1.  
The IMMPACT recommendations do not require that all outcomes are included in 
each trial, but states that the reasons for omission should be reported when domains 
are omitted from a study. HRQoL is not included as an outcome domain in the 
IMMPACT recommendations, but it is recommended to consider the inclusion of a 
HRQoL instrument for the assessment of self reported functioning.  
Table 1: IMMPACT core outcome domains and recommended instruments.
Outcome domains sures Recommended outcome mea
Pain  S is not feasible
one, mild, moderate, severe) 
11 point numeric rating scale (NRS) or if NR
Verbal rating scale (n
Usage of rescue analgesics 
Physical functioning e and one of the following: 
 instrument or
e ference items or
ntory interference scale  
ates
g of 
provement and satisfaction 
e events 
eporting
SF-36 physical functioning scal
A disease specific physical functioning
Brief Pain Inventory int r
Multidimensional Pain Inve
Emotional functioning Beck Depression Inventory and/or
Profile of Mood St
Participant ratin Patient global impression of change 
im
with treatment 
Symptoms and adverse effects Passive capture of spontaneously reported advers
and symptoms and use of open ended prompts. 
Participant disposition As recommended in Consolidated Standards of R
Trials (CONSORT) guidelines. 
An expert working group of the European Association for Palliative Care (EAPC) h
presented recommendations for the measurement of pain in palliative care research 
(Caraceni et al. 2002). An 11-point Numeric rating scale (NRS), a 100 millimetres 
Visual analogous scale (VAS) or a Verbal rating scale (VRS) is recommended f
unidimensional assessment of pain while the short form of the Brief pain invento
(BPI) or th
as
or
ry
e MacGill Pain Questionnaire is recommended for multidimensional 
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assessment of pain. The authors state that among the unidimensional measures the 
owever, a 
 to 
o
e to 
ed. For 11 point (0-10) NRS a 
duction of 2 or of 30% has been demonstrated to be clinically significant (Farrar et 
studies are needed to address this important topic.     
ains
he keystone in the evaluation of pain patients is the medical history, clinical 
ity of 
r
hile
le functioning, emotional 
distress/depression and cognitive functioning. Contrary to the situation in clinical 
 be available to the clinician 
immediately after the questionnaire has been completed. This is an obstacle to the 
n of HRQoL instruments like the SF-36 or EORTC QLQ-C30 
VRS is the easiest and VAS the most difficult for patients to comprehend. H
VRS with few response alternatives may have a poor sensitivity and responsiveness
change. The use of a HRQoL instrument, preferably the EORTC QLQ-C30, is 
recommended when a broader assessment than pain is desired in palliative care 
research.
To allow solid conclusions from clinical trials, the study design needs to be 
appropriate and differences need to reach both statistical and clinical significance. 
Because statistically significant differences may be too small to be noticeable to the 
patient or too small to be worthwhile when risks, side effects and resources are als
considered, the magnitude of change which is clinically significant needs to be 
determined. When the clinically significant change is determined it is also possibl
report the proportion of patients experiencing clinically significant positive effects 
and the number needed to treat (NNT) can be calculat
re
al. 2001). For the EORTC QLQ-C30 HRQoL questionnaire a change of 10-20 in 
either direction is described by patients as a moderate change and is considered 
clinically significant (Osoba et al. 1998). Following these data, mean differences 
between groups in the same rage are also considered clinically significant, but more
In clinical research the wish for comprehensive assessment of all relevant dom
needs to be balanced against the burden to the patients. A too heavy burden for the 
patients poses ethical dilemmas and may cause withdrawal from the study. These 
issues are also addressed in the IMMPACT recommendations (Turk et al. 2003).
Assessment in clinical routine 
T
examination and supplementary investigations such as laboratory tests and diagnostic 
imaging. However, systematic assessment of symptoms, comorbidities and qual
life adds information which is useful in the clinical decision making. Chronic pain is
as mentioned above associated with depression, reduced HRQoL, fatigue and reduced
functioning as well as reduced neuropsychological performance.  
No standard for symptom assessment in patients with CNMP admitted to pain clinics 
has been developed. Even though one MDPC have developed and validated an 
instrument which they recommend for routine clinical evaluation of symptoms and 
quality of life in CNMP patients (Rogers et al. 2000b) the applied instruments diffe
between clinics. Some pain clinics have developed “local” pain questionnaires, w
others apply various types of questionnaires developed for research. Domains 
included are often pain and other symptoms, physical and ro
research, information gathered for clinical use needs to
clinical applicatio
containing multi-item scales. On the other hand instruments like the BPI, where 
scoring is not required, are suitable for clinical application. 
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Opioids in chronic non-malignant pain 
Introduction 
In this part of the introduction the use of opioids in the treatment of CNMP
will be discussed. Efficacy, guidelines, long term data, population data, concerns 
about opioid treatment, opioid switching, opioid pharmacogenetics, methadone as an 
analgesic and methadone pharmacology will be mentioned.  
Epidemiology of opioids in chronic non-malignant pain 
On average 5 and 23% of the European population reporting CNMP in an 
epidemiologic study received treatment with strong and weak opioids respectively 
(Breivik et al. 2006). A variation between countries from 0 to 13% in the use of strong
opioids and from 5 to 50% for weak opioids was reported. The authors concluded tha
this large variation in opioid use indicates a need for better and more common 
guidelines. Other data on opioid consumption among patients with CNMP in
 conditions 
t
 the 
ish study 9% and 3% of the population reporting pain 
id treatment of CNMP have been 
pub h lverket
200 hough
clinical practice differs som
agreem sed on 
the f ll
x
x
l
opioid
ugh
re exceptions  made fo  who most of the time have mild 
population are sparse. In a Dan
in an epidemiologic survey used weak and strong opioids respectively (Eriksen et al. 
2003) while the estimates for Denmark presented by Breivik et al were 8% and 11% 
respectively. According to Danish data 73% of patients admitted to a MDPC were 
receiving either weak or strong opioids at admittance (Becker et al. 1997).   
Indications / guidelines 
Dur g in the last years several guidelines for opio
lis ed by experts, organizations and national regulatory bodies (Legemidde
2;Kalso et al. 2003;Nicholson 2003;The British Pain Society 2004). Even t
ewhat between countries and cultures, there is general 
ent between the above mentioned guidelines that treatment should be ba
owing principles:  o
x A thorough examination of the patient.  
All other therapeutic interventions have been tried or have been found 
contraindicated.
x Opioid therapy is initiated by a pain specialist after discussion with the 
patient’s general practitioner.
A clear agreement between doctor and patient about indications for 
termination of opioid treatment, possibly in the form of a signed treatment 
contract.
x
x The effect on pain and functioning needs to be evaluated at the end of a trial 
period and later at regular intervals.
One doctor handles all opioid prescription to each patient.
x Use of fixed doses of long acting opioids or slow release formulations. Severa
opioids are available (table 2). 
x No use of short acting opioids.
x A more careful approach is necessary in patients with known personal or 
family history of substance abuse or a poor psychosocial functioning.
Contrary to the situation in cancer pain (Hanks et al. 2001), the guidelines for 
ent of CNMP co do not allow ids for breakthrotreatm nditions  short acting opio
pain. Ra  are, however, r patients
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pain which does not r ioid treatment but on some rare occasions experience 
uciating i
ailable op g half ti  release formulations.  
ade name in Norway 
equire op
pain of excr ntensity.
Table 2: Av ioids with lon me or slow
Opioid Formulation Tr
Morphine Slow release p.o. Dolcontin®
Oxycodone Slow release p.o. OxyContin®
p.o. Metadon® Methadone
Fentanyl Transdermal Durogesic® 
Buprenorphine Transdermal Norspan® 
Hydromorphone Slow release p.o. Palladon® 
Ketobemidone Slow release p.o. Ketodur® 
Tramadol Slow release p.o.  Nobligan®  
Dihydrocodeine Slow release p.o. * 
Codeine Slow release p.o. * 
* Not commercially available in Norway. 
Efficacy  
Recent reviews have summarized the available data from trials of opioids in CNMP 
conditions where other therapies fail to provide satisfactory pain relief (Ballantyne 
and Mao 2003;Kalso et al. 2004). Kalso et al identified and included four RCTs of 
intravenous opioid testing and eleven RCTs of oral opioids vs. placebo in their review
(Kalso et al. 2004). Treatment periods in the latter group lasted from 4 days to 8 
weeks. The included patients experienced a mean reduction in pain intensity of at 
st 30% while 80% experienced one or more side effects. There were large 
Eriksen
 This finding could be a result of biases from the non-randomised study 
g
r
 The authors found evidence neither for one particular opioid being preferable 
cting opioids. However, the review concluded 
lea
differences between studies in the reporting of outcomes other than pain. However, 
improved sleep was indicated while no clear trend towards improved functioning or 
quality of life or decreased depression was observed. In a recently published cross 
sectional epidemiologic study CNMP patients on long term opioid therapy reported 8
to 25 points poorer HRQoL scores in all SF-36 scales and a smaller proportion was 
employed (32% vs 55%) compared to CNMP patients not on opioid therapy (
t al. 2006).e
design but the authors speculate that opioid treatment may contribute to a worsenin
of the pain condition in the long run.
A recent review of opioids in chronic neuropathic pain identified six RCTs (Eisenberg 
et al. 2005). These studies reported improved pain control from opioids compared to 
placebo, with an average benefit of 14 millimetres on a 100 millimetres VAS. 
However, side effects were prevalent with number needed to harm (NNH) of 3.6 fo
nausea, 4.6 for constipation, 5.3 for drowsiness, 6.2 for vomiting and 6.7 for 
dizziness.
Studies comparing different long acting opioids or short acting versus long acting 
opioids for CNMP have recently been subject to a systematic review (Chou et al. 
2003).
nor for choosing long instead for short a
that high quality trials are lacking and that the available data are inadequate for solid 
conclusions. In an open study published after this review a conversion from short 
acting or on demand opioids to a long acting opioid reduced the prevalence of 
breakthrough pain from 90 to 70% (Hojsted et al. 2006). This finding indicates that 
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stable use of long lasting opioids without on demand use of short acting opioids 
provides the most stable pain control. More importantly the data also showed that 
CNMP patients on opioid therapy must expect to experience periods of increased 
pain.
Data from long term follow up 
Three studies in the previously mentioned review by Kalso et al also reported results 
from long term open label follow up lasting from seven to 24 months (Kalso et a
2004). On average 44% of included patients were still on opioids at the end of follo
up. Recently published follow up data on 160 patients (57% of patients still being
alive) ten years after MDPC treatment in Denmark revealed that increase and decrease
in opioid dose was equally common (Jensen et al. 2006). The patients decreasing their 
dose had a mean dose reduction of 70% while the patients increasing their dose h
mean increase of 64%. In three patients major dose escalation occurred with fo
doses about 1100 mg oral morphine /24h. While 89% of patients discharged on opio
therapy received a single long acting or slow release opioid at discharge, only 60%
patients receiving opioids at follow up used a single long acting or slow release
opioid. The remaining patients used either a single short acting opioid (28%) or a 
combination of opioids (13%). 28% of patients discharged from MDCP without 
opioid therapy had initiated opioid therapy after discharge, and in 72% of these cases 
a short acting weak opioid was used. A German MDPC performed a follow up survey 
of CNMP patients having started opioid therapy three to nine years (average 66 
months) earlier (Maier et al. 2005). It was possible to include 35% of the 345 
approached patients. An opioid discontinuation rate of 15% was observed, with
l.
w
ad a 
llow up 
id
 of 
 the 
een a half and one year after start of 
e reasons for discontinuation were poor efficacy in 14 of 18 
seline
sed
to long 
me opioid 
e the risk for development of addiction or 
iversion of prescription opioids, dose escalation, 
and
).
 the 
majority of discontinuations occurring betw
opioid therapy. Th
patients, side effects in two patients and fear of addiction in two patients. At ba
52% of patients received WHO step three opioids while this percentage had increa
to 75% at follow up. 12% of patients received a short acting opioid in addition 
acting or slow release formulation at follow up. Of the patients taking the sa
at follow up and baseline, a third used the same dose, 16% had decreased the dose and
27% had a slight increase in dose while 19% received what the authors described as 
high dose-treatment, which unfortunately was not clearly defined in the text.
Concerns
While it is documented that some CNMP patients respond well to opioids and 
continue treatment with quite stable doses for several years, there are still several 
areas of concern. These areas includ
aberrant drug behaviour, d
development of abnormal pain sensitivity and influence on cognitive functioning 
the immunological and endocrine systems (Savage 1999;Ballantyne and Mao 2003
It is also a concern that a majority of CNMP patients treated with opioids receive 
short acting opioids or a combination (Becker et al. 1997;Breivik et al. 2006). The 
evidence for long term beneficial effects on functioning and HRQoL is also yet to be 
established in high quality prospective trials with long follow-up periods, and
beneficial effect of opioids for CNMP has been questioned (Eriksen et al. 2006).  
 17 
Opioid switching
Many CNMP patients do as previously mentioned, not experience an acceptable 
balance between pain control and side effects following start of opioid therapy. In 
these cases other therapeutic interventions need to be considered. However, because 
one of the indications for opioid treatment usually is that all other options have been 
exhausted, the available options are few. It has been indicated that successive trials
different opioids increase the responsiveness to opioid therapy in this patient 
population, and accordingly a switch of opioid might be an
 of 
 option when the first line 
t
id
ene). Even though this genetic variability may cause clinically significant 
orphine, the polymorphism with the most 
ent is the polymorphism which inhibits
etabolisers of codeine (Chen et al. 
reliminary models for how information 
es
r
05).
ethadone in pain treatment 
.
opioid fails (Quang-Cantagrel et al. 2000). In the literature both “opioid rotation” and 
“opioid switching” describe this substitution of one opioid with another.   
Even though an acceptable balance between pain control and side effects is achieved 
in the majority of cancer patients after adequate dose titration with a first line opioid 
(Ferreira KA et al. 2006), it has been reported that successive trials of different 
opioids increase the responsiveness to opioid therapy (de Stoutz et al. 1995;Riley e
al. 2006). Recent review papers have concluded that the level of evidence for opio
switching for cancer pain is low, but that the large number of case series and open
and/or retrospective studies indicate that opioid switching is effective in this 
population (Quigley 2004;Mercadante and Bruera 2006).
The mechanisms for the effect from opioid switching have not yet been established, 
but several different mechanisms can be hypothesized. These include differences 
between opioids in receptor binding profiles, effects on receptors other than the ȝ-
opioid receptor, effects from active metabolites and differences in pain mechanisms 
between different pain conditions. In addition there is rapidly growing evidence for 
genetic influence on individual responses to the different opioids. Several genetic 
polymorphisms have been reported to influence the clinical efficacy of morphine 
(Klepstad et al. 2005). These are polymorphisms in genes coding for morphine 
metabolism (UGT2B7gene), the µ-opioid receptor (OPRM gene) and blood brain 
arrier transport of morphine (MDR1 gene) as well as in non-opioid systems (COMTb
g
interindividual differences in the need for m
important clinical impact on opioid treatm
CYP2D6 formation of morphine in poor m
1988;Yue et al. 1991;Lotsch et al. 2004). P
about carrier status for several polymorphisms could be used to adapt morphine dos
have been presented (Lotsch and Geisslinger 2006), but routine genotyping before 
start of morphine therapy is not yet an option. The perhaps most interesting 
pharmacogenetic study for opioid switching is the study by Ross et al which reported 
an association between polymorphisms in the ȕarrestin2 gene (involved in µ-recepto
signalling) and the need to switch from morphine to other opioids (Ross et al. 20
M
History and areas of application 
Methadone was developed in Germany in 1938 by the doctors Max Bochmuhl and 
Gustav Ehrhart in the Hoechst factory and the patent was filed in 1941 (Fishman et al
2002). It is not known whether it was originally developed as an analgesic or 
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spasmolytic, but according to myth it was developed to relieve an anticipated shortage 
of morphine during World War II. When the Hoechst factory came under American 
control after the war, the formulation was published by the U.S. Department of 
Commerce. Methadone was first made commercially available by the company Eli-
Lilly under the name Dolophine.  
Methadone has had two major fields of application; in pain management and in op
maintenance therapy for opioid addicts in order to prevent abstinence reactions and 
relapse to misuse. Methadone had an important role in the treatment of long lasting 
pain until the development of slow-release formulations of other opioids in the ear
1980s. Until the slow release formulations were avai
ioid
ly
lable, prescription of methadone 
as preferred due to its long half life; the only way of avoiding five to six daily 
intenance therapy in the treatment of heroine addiction (Dole and 
Nyswander 1965;Joseph et al. 2000). Methadone maintenance programs are more 
ms without opioid substitution therapy in terms of decreased 
 other 
e
ethadone has the chemical structure of
igure 1), is lipophylic and is basic with an pKa of 9.2. The distribution volume of 
.6 L/kg is caused by an extensive tissue reservoir (Inturrisi et al. 1987). Also plasma 
rotein binding is high, approximately 90% (Inturrisi et al. 1987), with binding to Į1-
lycoprotein dominating (Eap et al. 1990). Commercially available formulations of 
ethadone are racemic mixtures of R- and S-methadone (levomethadone and 
extromethadone respectively). R-methadone is responsible for the ȝ-opioid receptor 
istensen et al. 1995). However, i
MDA) receptor antagonistic action from 
w
opioid administrations. However, methadone was at that time primarily available as a 
mixture with an unpleasant taste, and methadone soon lost popularity after the slow 
release formulations of other opioids were introduced. Methadone was used for the 
treatment of opioid abstinence already in the 1950s. In the mid 1960s it was first used
in opioid ma
effective than progra
heroin use and retainment in rehabilitation therapy (Mattick et al. 2003). The most 
common alternative to methadone in opioid maintenance treatment is buprenorphine
but there is no evidence supporting that buprenorphine is a better alternative than 
methadone in adequate doses (Mattick et al. 2004). 
Methadone is cheaper than equianalgesic doses of slow release formulations of
opioids, and for some patients savings in the magnitude of 70% have been reported 
(Gardner-Nix 1996). However, because of variations between countries in the relativ
prices and interindividual differences in dose-ratios, the potential for cost reductions 
is variable.
Pharmacology 
M  6-dimethylamino-4,4-diphenyl-3-heptanone
(f
3
p
g
m
d
mediated analgesic effects of methadone (Kr n vitro 
trials have indicated N-metyl-D-aspartate (N
S-methadone due to non-competetive binding (Gorman et al. 1997).  
Figure 1: Methadone structural formula 
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Methadone is metabolized primarily by the hepatic CYP 3A4 (Iribarne et al. 1996), 
but also by CYP 2B6 (Kharasch et al. 2004b). The metababolic activity of CYP 2D6 
as been reported to play a significant role for response to methadone maintenance 
dies have 
5-
ol
n the blood brain barrier and 
testinal epithelium (Schinkel 1997). It acts as en efflux pump and at these locations 
e
 to be an inhibitor of P-glycoprotein. P-glycoprotein inhibition 
ith quinidine increased the oral bioavailability of methadone, while it did not alter 
teers
otein
y
ossible
l.
fter oral administration of methadone bioavailabilities of 86% (range 75-97) is 
)
y
 study of opiate 
isusers in detoxification (Nilsson et al. 1982a). Methadone half-times between 7 and 
 leads to increased metabolism 
 autoinduction (Sawe 1986). Autoinduction has been hypothesized based on data 
h
therapy (Eap et al. 2001), but its role in methadone metabolism has not been 
established. Several other CYPs have also been hypothesized to metabolise 
methadone (Garrido and Troconiz 1999). Even though hepatic methadone N-
demetylation in vitro is not stereoselective (Foster et al. 1999), clinical stu
indicated that methadone metabolism and disposition is stereoselective (Foster et al. 
2000;Foster et al. 2004). Neither the primary methadone metabolite 2-ethylidene-1,
dimethyl-3,3-dipenylpyrrolidine (EDDP) nor the less important metabolites methad
and 2-ethyl-5-methyl-3,3-diphenylpyrolidine (EMDP) are known to be 
pharmacologically active. In addition to the hepatic metabolism of methadone, also 
intestinal first pass metabolism has been indicated (Oda and Kharasch 2001;Kharasch 
et al. 2004c).
P-glycoprotein also known as multi drug resistance protein 1 (MDR1) is located in 
several tissues including the capillary endothelium i
in
it is believed to limit the concentration in the cerebrospinal fluid and oral 
bioavailability respectively. Experimental studies in mice have indicated methadon
and several other opioids as substrates for P-glycoprotein (Thompson et al. 2000). 
Quinidine is known
w
the pharmacodynamics following intravenous methadone administration in volun
(Kharasch et al. 2004a). While polymorphisms in the gene coding for P-glycopr
does not seem to be of clinical relevance for the pharmacokinetics of orall
administered methadone (Lotsch et al. 2006) data from opioid substitution therapy 
indicate that genetic variability in the MDR1 gene may influence the required dose of 
methadone (Coller et al. 2006;Crettol et al. 2006).
Due to metabolism by CYP 3A4 and 2D6, methadone is subject to numerous p
interactions which may influence half time and serum concentration (Ferrari et a
2004). For CYP 3A4 both induction and inhibition is possible, while CYP 2D6 can 
only be inhibited.
A
reported in healthy volunteers (Dale et al. 2002), 79% (range 60-92) for cancer 
patients (Gourlay et al. 1986) and 80% (range 41-99) in opiate addicts in 
detoxification (Meresaar et al. 1981). Time to maximum serum concentration (Tmax
after oral intake was reported to be 2.1 hours (range 1.5 to 2.8) in one study of health
volunteers (Dale et al. 2002) compared to 3 hours (range 1-5) in a
m
65 hours have been reported (Gourlay et al. 1986). Urinary pH has significant 
influence on methadone elimination and half times (Nilsson et al. 1982b). Even 
though changes in urinary pH can explain changes in elimination half times in one 
individual, it explains only about ¼ of the interindividual variation (Rostami-
Hodjegan et al. 1999). 
It has been suggested that chronic methadone treatment
by
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reporting decreasing serum concentrations during long-term methadone treatment 
with stable doses in opioid maintenance treatment (Verebely et al. 1975;Anggard et 
al. 1975;Holmstrand et al. 1978;Rostami-Hodjegan et al. 1999).
Data from patients in opioid maintenance therapy have showed low correlation 
between methadone dose and steady state serum concentration (de Vos et al. 1995), 
nd that methadone dose can only explain about half the variability of methadone 
so the latter study 
ported patients with outlying serum concentrations.  
 reported that the 118A>G mutation in the OPRM1 gene coding 
ecreased effects of levomethadone when 
ter a single oral dose in healthy volunteers (Lotsch et al. 
 association between the effect of methadone and 
te genes which were genes coding for P-
d CYP 3A, 2D6, 1A2, 2C8, 2C9, 2C19 and 2D6.
terindividual differences in several of the mechanisms described above may 
ble pharmacokinetics of methadone. The factors which 
lity are summarized in table 3.
a
serum concentrations (Eap et al. 1998). Contrary to this, one study found a high
correlation between daily oral methadone doses adjusted for body weight and plasma
concentrations of methadone (Wolff et al. 1991). However, al
re
Recently it has been
for the µ-opioid receptor is associated with d
assessed with pupillometry af
2006). This study found no
polymorphisms in the other included candida
glycoproteine an
In
contribute to the highly varia
may contribute to this variabi
Table 3: Factors which may contribute to interindividual variability in methadone 
pharmacokinetics. 
Factors which may influence methadone pharmacokinetics 
Tissue reservoir (body composition) 
Levels of plasma proteins 
Metabolic activity of involved CYPs 
Urinary pH 
Drug-drug interactions 
First pass metabolism 
P-glycoprotein activity 
Equianalgesic dosing
ed
1998). Some studies of opioid switching have applied dose dependent dose ratios 
(Ripamonti et al. 1998b) while others have applied a fixed dose ratio of 5:1 
(Mercadante et al. 1999). 
While the traditional morphine:methadone dose ratios of 1:1 to 4:1 are still mention
in the last editions of the major textbooks in palliative medicine and pain medicine, 
the readers are now warned that dose ratios in opioid switching might be higher 
(Hanks et al. 2004;Schug SA and Gandham N 2005). Several studies of opioid 
switching have reported dose ratios which are substantially higher and with large 
interindividual variations (Lawlor et al. 1998;Ripamonti et al. 1998a;Ripamonti et al.
1998b;Gagnon and Bruera 1999). There are strong indications that the differences in 
ratio may be explained by dose-dependency (Lawlor et al. 1998;Ripamonti et al. 
1998b), but also interindividual differences in oral bioavailability and metabolism 
may influence dose ratios (Anderson et al. 2001). For very high pre switch morphine 
doses morphine to methadone ratios as high as 16:1 have been reported (Lawlor et al. 
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Because studies on equianalgesic doses are performed in clinical settings, the term 
“equianalgesic” dosing is often inaccurate. The reason is that the indication for 
switching to methadone was unacceptable pain control and that methadone rapidly is 
titrated to the dose providing the best balance between side effects and pain control. 
With few exceptions the reported equianalgesic dose ratios are really ratios between 
an opioid dose which provided dose limiting side effects in the presence of 
uncontrolled pain and the methadone dose which provided adequate pain control with 
an acceptable level of side effects.  For these reasons it has recently been suggested to 
use the term “initial conversion ratios” instead of “equianalgesic doses” when 
addressing dose ratios for switching between opioids (Mercadante and Bruera 2006
Methadone in cancer pain 
While morphine for reasons of familiarity, availability and cost rather than p
superior efficacy remains the first choice opioid in cancer pain (Hanks et al. 2001), 
methadone is frequently used as an alternative opioid in opioid switching. Some
RCTs have compared methadone to other opioids in the treatment of cancer pain. In a
Cochrane review of these
).
roven
 studies it was concluded that they had too short follow-up to 
determine if methadone could have long term benefits compared to other opioids, but 
 to be a better first line opioid 
s
pioid used 
l
dy
s of 
ydromorphone (10 patients) and morphine (2 patients) to oral methadone (Hays and 
f
that based on the available data methadone did not seem
(Nicholson 2004). However, in another Cochrane review it was concluded that 
methadone is the most frequently used second line opioid for cancer pain, and that 
opioid switching for some patients may be the only option for pain relief (Quigley 
2004). Even though a large number of studies have reported the successful use of 
methadone in opioid switching, high quality RCTs are lacking. The switch to 
methadone needs to be compared to switching to other opioids and to other 
therapeutic interventions. Opioid switching to methadone is in spite of low level of 
evidence recommended in the European association for palliative care (EAPC) 
guidelines for “Morphine and alternative opioids in cancer pain” when other opioid
fail (Hanks et al. 2001).
Methadone in chronic non-malignant pain
As in the treatment of cancer pain, methadone is primarily a second line o
in opioid switching in CNMP. In contrast to the situation in cancer pain, few studies 
have addressed opioid switching in CNMP. One case series,  one case report and four
studies have been published on opioid switching to methadone in CNMP patients 
(Gardner-Nix 1996;Thomsen et al. 1999;Hays and Woodroffe 1999;Quang-Cantagre
et al. 2000;Altier et al. 2001;Moulin et al. 2005). The first was a case series of five 
patients published in 1996 (Gardner-Nix 1996). Four of these patients experienced 
improved pain control, with NRS 2-4 on an 11 point scale several months after the 
switch to methadone. In a retrospective study, 17 patients were switched between
methadone and other strong opioids, among them seven from morphine to methadone
(Thomsen et al. 1999). Only cumulative data were reported, and the effect from 
switching from morphine to methadone cannot be properly judged. Another stu
reported improved pain control in patients switching from large dose
h
Woodroffe 1999). Based on a chart review an increasing number of patients starting 
opioid therapy for chronic non-malignant pain, achieved more than 50% pain relie
after sequential trials of different opioids including methadone (Quang-Cantagrel et 
al. 2000). One open prospective study included 50 patients with chronic neuropathic 
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pain which had not responded to an average of 2.8 previous opioids (Moulin et al. 
2005). 26 of these 50 patients reported mild to complete relief of pain and 14 patients
reported improved functioning at the end of follow up which was on average 14 
months after the switch to methadone. Successful use of methadone in the treatment 
of neuropathic pain poorly responsive to morphine in one patient following a burn 
injury has also been reported (Altier et al. 2001). Neither RCTs nor systematic 
prospective studies with long time follow up have been conducted. 
In addition to the studies of methadone in opioid switching, the use of methadone in 
e treatment of chronic neuropathic pain in the absence of malignant disease has 
ge
.
entage
%
s recently published their experiences from using methadone 
 a program for chronic pain patients with iatrogenic opioid dependency (Rhodin et 
e
iplinary pain centres, but below norm data. Most patients experienced 
improved functioning.  
o
es”
t in the 
ent were 
oughts like “others think I am an addict” and “methadone can harm me or my 
on
n healthy 
th
been evaluated in one RCT and one retrospective study (Morley et al. 2003;Altier et 
al. 2005). 19 patients not currently on opioid therapy were included in the RCT and 
reported reduced VAS scores for both maximum (16 of 100 – p=0.013) and avera
(12 of 100 – p=0.020) pain intensity with methadone 10 mg x2 (Morley et al. 2003)
In the retrospective study 13 patients taking methadone for chronic neuropathic pain 
were included (Altier et al. 2005). Four patients had stopped methadone due to side 
effects or no improvement in pain relief while the remaining nine patients were still 
taking methadone one year after its initiation. When patients reported their perc
of pain relief and improvements in quality of life and quality of sleep on 0 to 100
scales, mean improvements were 43% for pain intensity, 47% for quality of life and 
30% for quality of sleep.  
One centre in Sweden ha
in
al. 2006). During eight years 60 patients had met the criteria for inclusion in the 
program; age above 20 years, severe CNMP, dependence on opioids for more than 
one year, insufficient pain relief and low quality of life. At follow up on average 34 
months after start of methadone, 42 patients were still taking methadone while 18 had
left the program; three due to no pain and no need for opioids, four due to intractabl
nausea, one due to cardiac arrhythmia, four were excluded due to addiction or 
diversion, one experienced no pain relief  and five were dead. 36 of 42 patients 
reported good pain relief while the remaining patients reported moderate pain relief. 
Quality of life at follow up was substantially better than in patients admitted to 
multidisc
Recently a qualitative study in 11 patients scheduled to start of methadone for CNMP 
evaluated patients’ beliefs concerning start of methadone (Arnaert and Ciccotost
2006). The study identified an initial acceptance phase followed by a phase focusing 
on to which extent patients should disclose the treatment to their friends and family. 
During the acceptance phase the initial belief about “methadone being for junki
decreased as their knowledge of methadone as en analgesic as well as their trus
doctor increased. Fear of social stigma influenced whether patients were open about 
their treatment to their surroundings. Important barriers to methadone treatm
th
family”. 
Practical use
Methadone is commercially available as capsules and mixture for oral administrati
and in solution for parenteral administration. In experimental studies i
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volunteers methadone has been administered in a nasal spray device and in solution 
ily. In 
e
e
centrations of methadone, morphine and 
orphine metabolites have been reported in ten patients switching from morphine to 
ically
r weeks 
trategies, and almost all data 
are from studies in cancer patients.  
 of 
 the hospital and both 
e patients and their primary caregivers have been educated about the possible 
 is 
e
for rectal administration (Dale et al. 2002;Dale et al. 2004), but these formulations are
not commercially available. Use of custom made suppositories have also been 
reported (Bruera et al. 1995). Methadone parenterally can cause local toxicity 
reactions if administered subcutaneously (Bruera et al. 1991). Thus the intravenous 
route is preferable for long lasting parenteral administration.
Due to its long terminal half life, methadone can be dosed less frequently than other 
opioids. In methadone maintenance therapy methadone is administered once da
contrast to this, methadone for pain is usually administered three times daily 
(Mercadante et al. 1999). For some patients dosing twice daily is sufficient while 
some patients require 6 hourly dosing to achieve stable pain control.  
As methadone is rarely used as a first line opioid, therapy is usually started as part of
an opioid switch. Several ways of switching to methadone have been presented. Th
two dominating switching strategies can be described as “stop and go” and “the 3 
days method” (Mercadante and Bruera 2006). In “the 3 days method” the dose of th
original opioid is decreased stepwise (a third each day) for tree days and substituted 
with the equianalgesic dose of methadone (Ripamonti et al. 1997;Lawlor et al. 1998).
When switching according to the “stop and go” strategy, the initial opioid is abruptly 
terminated at the same time as an equianalgesic dose of methadone is initiated 
(Mercadante et al. 1999). Serum con
m
methadone in a “stop and go” manner (Mercadante et al. 2003). Minor dose 
adjustments were necessary and some variation in methadone serum concentrations 
were observed during the first three days, but improved pain control and methadone 
serum concentrations in what the authors considered to be therapeutic range were 
observed the day after the switch. Serum concentrations of morphine and morphine
metabolites reached negligible levels by day tree day after the switch. The authors 
concluded that these data support that the “stop and go” strategy is pharmacolog
sound. Other switching strategies include a gradual switch during two to fou
(Hays and Woodroffe 1999) and a “methadone ad libitum” strategy (Tse et al. 2003). 
So far no studies have compared the different switching s
Due to reported cases of late toxicity with sedation and respiratory depression 
(Ettinger et al. 1979;Hunt and Bruera 1995;Watanabe et al. 2002;Hernansanz et al. 
2006) some authors have recommended that patients should be hospitalized 
(Ripamonti et al. 1997) and ideally with monitoring of vital signs during initiation
methadone therapy (Watanabe et al. 2002). However, others find that switching to 
methadone at home is safe when there is a close follow-up from
th
complications (Mercadante et al. 1999;Hernansanz et al. 2006). One study 
recommends a slow rotation during several weeks if opioid switching to methadone
performed in outpatients (Hagen and Wasylenko 1999).  
Methadone and QT time prolongation 
The QT time on the electro cardiogram (ECG) measures the time from the start of 
ventricular depolarisation to the end of ventricular repolarisation. Several drugs ar
known to increase the QT time trough delayed repolarisation. Such delay leads to 
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increased risk of arrhythmia, particularly the potentially lethal torsade de pointes 
arrhythmia (Viskin 1999). If QTc (QT time corrected for heart rate) exceeds 0.500 
seconds there is a clinically significant risk of this arrhythmia.  
In 2001 and 2002 the first cases of torsade de pointes during methadone treatm
were published (Hays 2001;Krantz et al. 2002). These were followed by two more 
case series each including three patients with torsade de pointes during methado
treatment (Walker et al. 2003;Gil et al. 2003). The patients in both these latter studies 
had other known risk factors for torsade de pointes. In 2003 also a retrospective s
reporting an increase in QTc of 0.042 seconds following start of methadone and a 
correlation between methadone dose and QTc as well as a small increase i
following start of morphine was published (Kornick et al. 2003). However, of 190 
patients treated with methadone during the study period, ECGs before and after star
of methadone were only available for 42 patients, and a selection bias is probab
2003 Krantz et al also published a study indicating a dose relationship between 
methadone dose and QTc in the 17 patients who were previously reported to have 
developed arrhythmia (Krantz et al. 2003). The first prospective cohort study 
including 193 methadone maintenance patients at baseline and 68% of these at follow
up repor
ent
ne
tudy
n QTc 
t
le. In 
ted an increase in QTc of 0.011 seconds following start of methadone 
artell et al. 2003). Two cases of torsade de pointes during methadone therapy have 
been
 subjects from opioid maintenance therapy and 
alliative cancer care reported QTc prolongation in 32% of subjects (Cruciani et al. 
Recently two prospective studies including 118 and 160 subjects in opioid 
maintenance therapy reported a modest increase in QTc, with mean values of 0.014 
and 0.012 seconds respectively at six months follow up (Martell et al. 2005;Krantz et 
al. 2005). Martell et al had also included a twelve month evaluation, and reported that 
mean QTc had not changed significantly from six to twelve months. This study also 
included measurement of methadone serum concentrations in a subset of 44 patients 
at 12 months and found that QTc increases were significantly correlated to methadone 
serum concentration a year after start of methadone. Two patients reached QTc time 
above 500 milliseconds in this study.  
None of the prospective studies have reported cases of torsade de pointes arrhythmia 
and the risk of developing arrhythmia is not yet established. 
(M
also been reported in Norway (Ostvold and Topper 2005) Other cases have 
reported in other national journals (Sanchez Hernandez et al. 2005). The evidence 
concerning the influence of methadone on QTc has been conflicting. In a 
retrospective study including 11% of the patients receiving methadone in a palliative 
care centre no indication of increased QTc was found (Reddy et al. 2004), while a 
cross sectional study of 83 patients being on opioid maintenance therapy with 
methadone for at least 6 months reported that 83% of the subjects had longer QTc 
than expected from reference data (Maremmani et al. 2005). Another cross sectional 
study including a mixed sample of 104
p
2005).
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Methods
Patient cohorts
This thesis is based on studies performed in three patient cohorts: 
1. In papers I and II patients admitted to the multidisciplinary pain centre at 
Trondheim University Hospital from September 1999 to January 2002 are 
included. During this period all patients were encouraged to complete the 
HRQoL instruments SF-36 and EORTC QLQ-C30 electronically using a 
touch screen immediately before their first consultation. Out of 602 patients 
admitted to the multidisciplinary pain centre for chronic non-malignant pain 
during the study period, complete HRQoL data were available for 286 patients 
(included in Paper I). EORTC QLQ-C30 was completed by two more patients, 
and accordingly 288 patients were included in paper II. 
2. In paper II the HRQoL of CNMP patients admitted to the MDPC is compared 
to palliative cancer patients. From March 1995 until November 1997 patients 
were included in a trial of comprehensive palliative care (Jordhoy et al. 
2000;Jordhoy et al. 2001). The inclusion criteria were histologically verified 
malignant disease, life expectancy between three and nine months, age above 
18 years, completion of HRQoL data at baseline and living in one of the health 
care districts included in the study. The 395 included patients equal about half 
the number of patients dying from malignant disease in the included health 
care regions during the inclusion period (Jordhøy et al, Pall med 1999).  
3. For inclusion in the methadone switch study (Papers III, IV and V) all patients 
who had started treatment with strong opioids at Trondheim multidisciplinary 
pain centre were evaluated. Patients were identified through the staff’s 
knowledge of these patients. Out of 85 patients, seven were considered not 
suitable due to misuse of opioids and nine due to severe psychiatric 
comorbidity. Of the remaining 69 patients contact was established with 48. Six 
of these had stopped strong opioids, 20 experienced good pain control while 
eight did not want to participate. Two patients accepted to be included but had 
to withdraw prior to start of the study due to practical reasons. The remaining 
twelve were included in the study.
Study design 
Papers I and II are cross sectional studies. HRQoL in CNMP patients was measured 
immediately before their first consultation at the MDPC at St. Olav University 
Hospital, Trondheim, Norway. HRQoL data for palliative cancer patients in Paper II 
were collected at trial entry (i.e. when patients were admitted to palliative care).  
The methadone switch study presented in Papers III, IV and V was an open 
prospective pilot study without placebo treatment or randomization. Patients were 
followed for nine months with consultations at baseline, day one, two and three, after 
one, two and six weeks and at three and nine months.  
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EORTC QLQ-C30 
The EORTC QLQ-C30 questionnaire was developed for use in cancer patients and 
has been validated in such patient populations (Aaronson et al. 1993). The 
questionnaire has been translated to Norwegian, and the Norwegian translation has 
proven valid and reliable in cancer patients (Kaasa et al. 1995). The instrument covers 
social, physical, emotional, role and cognitive functioning, global quality of life, 
financial difficulties and the symptoms pain, fatigue, dyspnoea, diarrhoea, 
constipation, difficulties of sleep, nausea/vomiting and loss of appetite. During the 
scoring procedure all scales are linearly transformed into scales with range zero to 
100. In global quality of life and the five functioning scales a score of 100 
corresponds to a high HRQoL or high functioning. For financial difficulties and the 
eight symptom scales a score of 100 implies maximum of the symptom in question. A 
change of 10 points on the 0 to 100 scales is perceived as a moderate change and 
considered clinically significant (Osoba et al. 1998). Following this observation a 
difference 10 between groups is also regarded as clinically significant. EORTC 
QLQ-C30 norm data have been published for the Norwegian general population 
(Hjermstad et al. 1998). 
SF-36
The SF-36 questionnaire (Ware, Jr. and Sherbourne 1992) is a generic HRQoL 
instrument consisting of 36 questions. After the scoring procedure the results are 
presented in two symptom scales and six functioning scales; bodily pain, vitality, 
physical and social functioning, role physical and role emotional functioning, mental 
health and general health. All scales range from zero to 100 and a score of 100 
corresponds to a high HRQoL. The questionnaire has been translated to Norwegian 
and the translation has been validated (Loge et al. 1998). Norm data for the 
Norwegian general population have been published (Loge and Kaasa 1998). In spite 
of its wide application in CNMP populations, particularly the responsiveness of the 
SF-36 in this patient population has been questioned (Rogers et al. 2000a).
Brief pain inventory 
The Brief Pain Inventory (BPI) consists of numerical rating scales for pain intensity 
and impairment due to the pain condition (Cleeland and Ryan 1994). All scales range 
from zero to ten with zero being no pain/impairment and ten being the worst 
imaginable pain or impairment. The BPI is sensitive to changes in pain (Lydick et al. 
1995) and has been validated in patients with chronic non-malignant pain (Keller et 
al. 2004). The Norwegian translation has shown satisfactory psychometric properties 
in patients with cancer pain (Klepstad et al. 2002).
Neuropsychological tests 
In the methadone switch study three neuropsychological tests were used to assess the 
effects from the switch on cognitive functioning.  
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The Stroop Colour Naming Test (Spreen D and Strauss EA 1998) measures the 
relative speed of reading names of colours, naming colours and naming the colours of 
ink used to print incongruent colour names. The last task requires the ability to 
actively focus on the colour and override the over-learned tendency to read the word 
meaning. This is an adequate operationalization of selective attention, and the 
interference arising from such a conflict situation is called “the Stroop effect”. 
The Paced Auditory Serial Addition Task (PASAT) consists of a series of digits (one 
through nine) which are tape recorded and presented with a certain inter stimulus 
interval (Spreen D and Strauss EA 1998). In the present Norwegian version of the 
task, two subtasks with 2.0 and 1.5 seconds inter stimulus interval, respectively, were 
administered (Landro et al. 2004). The subject is required to add each digit to the one 
immediately preceding it (the second to the first, the third to the second, and so on) 
and give the answer orally. The score is the percentage of correct responses. The 
PASAT was introduced to the subject by writing the numbers on a sheet of paper 
while explaining the addition rules. Then an unpaced practice session was run to 
familiarize the subject with the task. The actual testing was not started until the 
subject showed a clear understanding of the basic principle. The PASAT is a clear 
operationalization of the executive control aspect of working memory. 
The Letter-Number Span task was selected as a measure of the capacity in working 
memory (Gold et al. 1997). The subjects are presented with a row of alternating letters 
and numbers and are asked to respond by first saying the numbers in order from 1-9, 
followed by saying the letters in alphabetic order. The test consists of 24 trials with 
increasing difficulty. The number of correctly recalled letter-number strings is 
recorded. 
Serum concentration analyses 
The effects from opioids are caused by binding to opioid receptors, primarily in the 
CNS. The pharmacological effects are related to the ligand concentration at the effect 
site. After oral administration opioids are absorbed from the gastrointestinal tract to 
the blood and the bioavailable fraction is further distributed to peripheral tissues 
including the sites of action. Due to interindividual differences in opioid 
pharmacokinetics and disposition, the serum concentration is a better indicator of 
opioid concentration at the effect site compared to opioid dose. Thus knowledge of 
the concentration-effect relationship may contribute to increased understanding of the 
dose-effect relationship for opioids. Moreover determination of serum concentrations 
of metabolites may contribute to increased understanding of the metabolism of the 
mother substance by calculating the metabolic ratio. In the case of active metabolites 
the determination of their serum concentrations is very important for the 
understanding of the dose-effect relationship.
Quantification of analytes (molecules) in serum was performed by liquid-
chromatography tandem mass-spectrometry (LC-MS/MS) (Tyrefors et al. 1996;Dass 
C 2000). The method is based on separation of the analytes by reversed phase liquid 
chromatography and further identification by their difference in mass-to-charge ratio 
(m/e) of the ionized atoms or molecules and their fragments. Molecules have 
distinctive fragmentation patterns and thus the method provides high specificity. 
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Morphine, M3G, M6G, normorphine, methadone and EDDP were isolated from 
serum by solid phase extraction and separated on a Zorbax SB-18 column. The 
analytes were then quantitated by a validated LC-MS/MS method (Perkin Elmer 200 
series HPLC system API 300 triple quadrupol mass spectrum) (Tyrefors et al. 1996). 
The limit of quantification was 1 ng/ml for all analytes. The standard curve range was 
1-50 ng/ml for morphine and normorphine, 1-60 ng/ml for M6G and 1-500 ng/ml for 
M3G, methadone and EDDP. The correlation coefficients were all >0.99. Interday 
coefficients of variation varied from 0.1 to 7 % for the 25, 50 and 75% levels of the 
standardcurves. 
Ethics
The use of the HRQoL data in paper I and II required no ethics committee approval. 
Data on the palliative cancer patients had been collected as part of a previous trial 
which had the necessary approval from the Regional Committee for Medical Research 
Ethics. The HRQoL and demographic data on CNMP patients had been collected for 
clinical purposes as part of clinical routine. The secretary of the Regional Committee 
for Medical Research Ethics, Health Region Central Norway approved the use of 
these data for research.
The methadone switch study (paper III, IV and V) was approved by the Regional 
Committee for Medical Research Ethics, Health Region Central Norway. The patients 
gave their informed consent to participation in the study. In the oral and written 
information to the patients the possible risk of sedation was emphasized and patients 
were instructed to contact a doctor if experiencing increasing drowsiness. During the 
opioid switch and the first month after the switch one of the investigators was 
available to the participating patients by phone around the clock. This measure was 
undertaken due to previous reports of severe side effects as well as the possibility that 
rare patients might experience severe increases in pain intensity when morphine was 
substituted with methadone. 
The studies included in this thesis have been conducted in accordance with the 
Helsinki Declaration (World medical association 2000). 
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Summary of papers 
Paper I 
Validation and comparison of the Health Related Quality of Life instruments SF-36 
and EORTC QLQ-C30 in assessment of patients with chronic non-malignant pain. 
The aim of this study was to validate the EORTC QLQ-C30 HRQoL questionnaire in 
the CNMP population and to compare advantages and disadvantages between this 
instrument and the more widely used SF-36 HRQoL questionnaire.  
The validation of the EORTC QLQ-C30 evaluated external convergent validity (how 
EORTC QLQ-C30 and SF-36 measures of the same concept correlated), internal 
consistency (reliability) in multi item scales, discrimination, sensitivity and construct 
validity.
Correlations between EORTC QLQ-C30 and SF-36 measures of the same concept 
were between 0.70 and 0.81 for all five domains covered by both instruments. Internal 
consistency was below 0.70 for the EORTC QLQ-C30 scales physical functioning 
(0.57), pain (0.68), role functioning (0.43), cognitive functioning (0.66) and 
nausea/vomiting (0.53) as well as the SF-36 scale role emotional functioning (0.66) 
while the remaining multi item scales exceeded the 0.70 limit. Large floor effects 
were seen for several EORTC QLQ-C30 scales, with values of 38-61% for 
nausea/vomiting, dyspnoea, appetite loss, constipation, diarrhoea and financial 
difficulties. Large floor effects were also seen for the SF-36 scales role physical 
functioning and role emotional functioning with values of 69 and 33 respectively. 
Construct validation indicated that the contents of the physical functioning scale differ 
between EORTC QLQ-C30 and SF-36. 
Even though some EORTC QLQ-C30 scales have unsatisfactory internal consistency 
and some of the symptoms are of little relevancy for a majority of chronic pain 
patients, the EORTC QLC-30 like the SF-36 shows acceptable psychometric 
properties.
Paper II 
Chronic non-malignant pain patients report as poor health related quality of life as 
palliative cancer patients. 
The HRQoL of 288 CNMP patients admitted to a MDPC were compared to 434 
palliative cancer patients and national norms. As HRQoL data are influenced by age 
and gender and these variables were unevenly distributed between the groups, age and 
gender adjustment was required. To adjust for age and gender differences between the 
two patient groups each patient’s deviation from the scores of the appropriate group in 
the general population was computed before mean deviations from norm data were 
estimated and compared.  
The 288 patients who completed the EORTC QLQ-C30 and met the inclusion criteria 
represented 48% of the 602 CNMP patients admitted to the MDPC during the study 
period. The included patients were on average five years younger than patients who 
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due to missing HRQoL data were ineligible (p <0.001, 95% CI 7.0–2.2). The 
percentage of females was similar, 61% and 64% respectively (chi-square test: 
p=0.47), as was also the distribution of pain diagnoses. 
Both patient groups reported worse scores in all scales compared to the age and 
gender adjusted general population. When comparing the deviations from norms 
between the CNMP and the palliative cancer patients, the CNMP patients were found 
to report larger deviations (worse scores) for five scales; cognitive function (23 vs 
10), global health (38 vs 31), pain (61 vs 22), sleep disturbances (36 vs 15) and 
financial impact (31 vs 7) as compared to the palliative cancer patients patients. The 
palliative cancer patients reported larger deviations (worse scores) for four scales; role 
functioning (53 vs 42), nausea/vomiting (20 vs 8), loss of appetite (41 vs 17) and 
constipation (27 vs 11) as compared to the CNMP patients. All differences were 
statistically significant, and except for global health, they were also clinically 
significant. For the remaining six functioning and symptom scales, no significant 
differences were found between groups.
Paper III 
Opioid switching from oral slow release morphine to oral methadone may improve 
pain control in chronic non-malignant pain: a nine months follow-up study. 
Twelve patients with poor pain control or unacceptable side effects during treatment 
with morphine were switched to methadone and followed for nine months in this open 
prospective study. Primary outcomes were patient preference of opioid and pain 
control while physical, cognitive and role functioning were secondary outcomes. 
Effects on other HRQoL domains as well as cognitive functioning were explored. BPI 
was used for assessment of pain, EORTC QLQ-C30 for HRQoL, Stroop, PASAT and 
Number Letter Span for cognitive functioning.  
The morphine dose was decreased with 1/3 daily and was replaced with an 
equianalgesic dose of methadone over a three days period. For doses <200 mg 
morphine po/24h a morphine:methadone dose ratio of 4:1 was applied while a ratio of 
6:1 was applied for higher doses. During switching and a one week dose titration 
period, patients were given additional methadone if required.  
During dose titration one patient experienced sedation requiring naloxone. Four 
patients were switched back to morphine due to poor pain control, drowsiness or 
sweating. Seven patients preferred long-term (> nine months) treatment with 
methadone and reported reduced pain and improved functioning while cognitive 
functioning was not improved. EORTC QLQ-C30 symptom scales indicated a 
temporary increase in the nausea and vomiting scale immediately after the switch. 
This study brings novel information on the long term consequences for pain control, 
HRQoL and cognitive functioning from a switch from morphine to methadone in the 
treatment of chronic non-malignant pain. 
Paper IV 
Long term methadone for chronic pain: a pilot study of pharmacokinetic aspects. 
Twelve patients treated with morphine for chronic non-malignant pain were switched 
to methadone. Seven of these patients continued with methadone throughout the nine 
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months study period and only minor dose adjustments were performed. Serum 
concentrations of morphine, methadone and their metabolites were measured at 
baseline, day one and two, after dose titration and one week, five weeks, three months 
and nine months after the end of dose titration.
Serum concentrations of methadone and its metabolite EDDP did not change 
significantly from the end of dose titration and during the nine months of follow up 
(repeated measures ANOVA: p=0.88 and p=0.06). Very low correlation between dose 
ratios and serum concentration ratios between morphine and methadone was 
observed. Total daily oral methadone dose at three months could not explain serum 
concentrations of methadone (R2=0.06 – p=0.61). Serum-concentration of EDDP one 
week after the end of dose titration varied six-fold (range: 12 to 69 ng/ml), and was 
explained by serum concentration of methadone (R2=0.77 – p=0.004).
At baseline traces of methadone were detected in three patients and in one of them 
also traces of EDDP. In one patient not reporting use of morphine or codeine after the 
switch, morphine-glucuronides in serum were observed at three months. In another 
patient M3G/morphine and M6G/morphine ratios of 215 and 36 were observed 
compared to average ratios of 104 and 19 in the rest of the patients. However, a rapid 
decline in serum concentrations of M3G and M6G was observed when morphine was 
substituted with methadone. In one patient the level of normorphine exceeded twice 
the levels in other patients while his serum-concentration of morphine was one of the 
lowest.
Our findings contradict that autoinduction of methadone metabolism takes place 
during long term treatment and supports that a 3-day opioid switch from morphine to 
methadone followed by a one week titration seems pharmacologically sound. Large 
interindividual differences in opioid metabolism were observed and the findings 
indicated that some CNMP patients consume other opioids in addition to the 
prescribed dose.  
Paper V 
Opioid switching from morphine to methadone causes a minor but not clinically 
significant increase in QTc time: a prospective 9 months follow-up study. 
Twelve CNMP patients switching from morphine to methadone due to unsatisfactory 
pain control or intolerable side effects were followed with ECGs at baseline, two 
weeks after the switch and three and nine months after the switch. From the ECGs the 
QTc time (QT time corrected for heart rate, QTc=QT/¥RR) was calculated. An 
experienced cardiologist measured QT time and RR intervals and screened the ECGs 
for factors affecting the QT time.  
The mean QTc time increased from 0.416 before start of methadone to 0.436 two 
weeks after start of methadone (mean change =0.020, 95% CI 0.007-0.032, p=0.01). 
The changes in the follow-up observations of QTc time were not statistically 
significant (repeated measures ANOVA, p = 0.90), indicating that duration of QTc 
time was not associated with time from the switch to methadone. At the nine months 
follow-up the ECG from one patient showed a supraventricular tachycardia and could 
not be used for comparison of QTc time. An additional ECG obtained two months 
later (sinus rhythm) showed a minor increase in QTc compared to the three months 
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follow-up. At the 9 months follow-up ECG recordings only precordial leads were of 
satisfactory quality for assessment of QTc time in one patient while one patient 
presented a right bundle branch block. No QTc times above 0.50 seconds or episodes 
of arrhythmia were observed. 
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Discussion
Research question 1 
Health related quality of life assessment methodology in chronic non-malignant pain 
patients: 
Is the EORTC QLQ-C30 a valid alternative to the SF-36 for assessment of HRQoL in 
CNMP patients?
In spite of unsatisfactory internal consistency in three scales the EORTC QLQ-C30, 
like the SF-36, demonstrated overall satisfactory psychometric properties. In the 
methadone switch study the EORTC QLQ-C30 also demonstrated to be responsive to 
change over time in CNMP patients, as improvements in several scales were detected 
in the patients choosing to continue long lasting methadone therapy. The overall 
acceptable psychometric properties are in accordance with previous studies in cancer 
patients where both instruments have performed well (Apolone et al. 1998;Kuenstner 
et al. 2002). An advantage of the EORTC QLQ-C30 compared to the SF-36 is that 
EORTC QLQ-C30 also addresses cognitive functioning and a broader spectrum of 
symptoms. Difficulties of sleep and financial problems have a high prevalence in this 
patient population which may warrant evaluation in clinical routine. Nausea/vomiting 
and constipation are frequent side effects of opioid therapy (Kalso et al. 2004) and 
thus should be relevant in clinical trials as well as clinical evaluation of patients on 
opioid therapy, although being of minor relevance for the majority of CNMP patients. 
For the symptoms nausea/vomiting, dyspnoea, appetite loss, diarrhoea and 
constipation floor effects of 43 to 61% were seen together with ceiling effects of 0.3 
to 6.6%. This could indicate poor ability to differentiate between no symptoms and 
mild symptoms, but based on clinical experience it is probably at least partly a 
consequence of low prevalence of these symptoms in this patient population. In the 
EORTC QLQ-C30 scales role functioning, insomnia and financial difficulties floor 
effects of 13 to 38% were seen together with ceiling effects of 21 to 26%. For 
insomnia and financial difficulties this is probably a consequence of the narrow 
response range with only 4 response alternatives. For role functioning this distribution 
indicates that contrary to the other functioning scales, a large part of patients with 
chronic non-malignant pain experience either very poor or excellent role functioning. 
The poorer Chronbach’s alpha values observed in our study compared to validation 
studies in cancer patients indicate that EORTC QLQ-C30 internal consistency is 
higher in cancer patients than in patients with CNMP for physical functioning, role 
functioning and nausea/vomiting. There is no obvious explanation for these 
differences in internal consistency between the two patient populations but it is 
possible to speculate on possible explanations. A possible explanation is that chronic 
pain affects more specific functional areas compared to advanced cancer disease. For 
instance would localised pain conditions be expected to have a strong influence on 
some functions but less on other. Such specific impact on functioning would reduce 
the internal consistency. 
The data indicated differences in content in the physical functioning scales between 
SF-36 and EORTC QLQ-C30. There are several possible explanations for this 
finding. While the SF-36 physical functioning scale consists of ten items, the QLQ-
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C30 only contains five physical functioning items. Most of the SF-36 questions are 
very specific compared to the wider and vaguer questions in the EORTC QLQ-C30. 
While SF-36 addresses problems with walking more than one mile EORTC QLQ-C30 
asks about a long walk. Another possibly important difference is that the EORTC 
QLQ-C30 uses carrying a suitcase as an example of strenuous activity, while the SF-
36 has running and participation in sport activities as examples of strenuous activity.
A possible limitation to the validation study is that HRQoL data were only available 
for 48% of patients admitted to the MDPC during the study period. It is possible that 
patients with a very poor HRQoL are overrepresented in the group with lacking data. 
In this situation particularly the floor- and ceiling effects would be affected. Data for 
the study were collected electronically on a computer with a touch screen as part of 
the clinical routine. It can be hypothesized that electronic data collection could cause 
a selection bias because older patients who are not accustomed to computers would 
avoid the data collection. However, in a study comparing the paper version and a 
computerised version of the SF-36 two thirds of patients preferred the electronic 
version, the electronically collected dataset had less missing data and scores were 
equal (Ryan et al. 2002). When HRQoL data were collected for clinical use as part of 
the initial evaluation it is possible that the patients’ responses could be consciously or 
unconsciously influenced. Reasons for this could either be a desire to justify the need 
for extensive treatment or a desire to be brave or tough. 
Research question 2 
Comparison of health related quality of life scores between patient groups: 
How is the HRQoL of CNMP patients admitted to MDPC treatment compared to the 
HRQoL of palliative cancer patients? 
The patients admitted to the MDPC reported equally poor or poorer HRQoL 
compared to palliative cancer patients in 11 of 15 EORTC QLQ-C30 scales. The 
CNMP patients’ HRQoL scores in this study are in the same range as previously 
reported from CNMP patients admitted to other MDPCs. An earlier study using the 
EORTC QLQ-C30 found a mean global health status score of 33 (Wincent et al. 
2003), compared to 36 for our patients. Other EORTC QLQ-C30 scores were not 
presented. Two previous studies using the SF-36 for HRQoL assessment found scores 
comparable to ours for all scales (Becker et al. 1997;Wittink et al. 2004). Although 
patient populations may differ between MDPC’s, there is no reason to believe that the 
patients in the present study are worse affected than patients admitted to other 
MDPCs.
When interpreting the results from our and other studies it is important to recognize 
that patients admitted to multidisciplinary pain clinics at university hospitals are a 
highly selected group. Even though the patient population in our study report similar 
HRQoL scores as the populations admitted to similar clinics (Becker et al. 
1997;Wincent et al. 2003;Wittink et al. 2004) the scores of these patients are 
representative neither for the large part of the population reporting chronic pain nor 
for patients admitted to less comprehensive pain clinics.  
The equally poor or poorer HRQoL of CNMP patients compared to palliative cancer 
patients may partly be explained by the “Calman gap” which explains reductions in 
HRQoL as the difference between what is experienced and what is expected (Calman 
1984;Carr et al. 2001). As CNMP patients do not have a life-threatening disease, they 
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may have higher expectations both to life in general and to the level of functioning 
than palliative cancer patients. An exception from this is the symptom pain where the 
large difference between the groups probably is a consequence of pain being the 
primary symptom in the CNMP group while not an inclusion criteria in the palliative 
cancer group. 
A limitation for the study representativity is that HRQoL data for CNMP patients 
were available for only 48% of the eligible population during the study period. There 
may be several reasons why patients did not complete the questionnaire: some days 
the computer was not available or there were technical difficulties, some patients did 
not have time to complete the questionnaire, some were unable due to poor health and 
some refused. The three first reasons would probably generate random failures, and 
thus not affect the study validity. Data missing for the last two reasons might, 
however, introduce bias. As indicated by the higher age of the non-responders it is 
reasonable to assume that non-responders had a poorer HRQoL than those who 
responded.
Other factors may also have affected the comparison of HRQoL scores. The possibly 
most important confounder is differences in socio-demographic variables. While 
appropriate adjustments have been made for the differences in age and gender, direct 
adjustment for differences in employment status was not possible and data on other 
socio-demographic variables were not available. Furthermore the palliative cancer 
group consists of patients included in a palliative care trial from 1995 to 1997 while 
data for the CNMP patients were collected for clinical use from 1999 to 2001. It is 
doubtful that the average HRQoL in any of the groups has changed significantly in 
four years, but the differing purposes of the data collection may have caused a 
selection bias.
Research question 3 
Opioid switching from morphine to methadone in chronic non-malignant pain 
patients with an unacceptable balance between pain control and side effects during 
morphine therapy:
What are the effects on pain control, HRQoL, cognitive functioning and patient 
preference? 
This prospective open pilot study evaluated the consequences of opioid switching 
from morphine to methadone in cases of unsatisfactory balance between pain control 
and side effects during morphine therapy for CNMP. An open pilot study can not 
determine efficacy or NNT but can indicate whether this treatment is successful in 
some patients. The experience gained from pilot studies will be helpful for future 
RCTs. The switch was effective in about half the patients and caused improved 
HRQoL scores and reduced pain. However, the other half of the patients experienced 
increased pain or intolerable side effects after the switch. As increased levels of pain 
in the latter group were poorly responsive to additional doses of methadone, some 
patients seem to be very poor responders to the analgesic effect methadone. On the 
other hand the case of sedation indicates that rare patients may experience serious side 
effects. In open studies the placebo effect may contribute to the outcomes. However, 
the stable pain and HRQoL scores during the nine months of follow up with stable 
methadone doses indicate that the effects are long lasting and probably not a mere 
placebo effect. The present study confirms the previously reported positive effects 
from opioid switching to methadone in this patient population, but is the first study 
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including follow-up beyond a few weeks (Thomsen et al. 1999;Hays and Woodroffe 
1999;Quang-Cantagrel et al. 2000). If the effect had not lasted beyond a few weeks 
after the switch it could have been questioned whether opioid switching to methadone 
is worthwhile as it poses a risk of increased pain as well as potentially serious adverse 
events.
Different ways of performing the switch from oral morphine to oral methadone have 
been reported in the treatment of cancer pain (Mercadante 1999;Bruera and Neumann 
1999;Hagen and Wasylenko 1999). In chronic non-cancer pain a gradual switch 
during two to four weeks has been applied (Hays and Woodroffe 1999). The stepwise 
switch applied in the current study has previously only been reported in cancer 
patients. In the present study one patient experienced drowsiness during dose titration, 
nine of twelve patients needed additional methadone to achieve acceptable pain 
control during switching and titration and two patients withdrew due to poor pain 
control during the switch. The different switching strategies have not been compared, 
but it can not be disregarded that the switching strategy chosen in this study might 
have affected the frequency of side effects as well as the overall success rate.  
The results are based on patient reporting. Patients have reported their opioid intake 
and they have completed self report instruments for the assessment of HRQoL and 
pain. For the first weeks of the methadone switch study the patients received from the 
investigator the number of methadone capsules needed until the next follow up 
consultation. Later methadone was prescribed to the patients. At each consultation the 
dosage until next consultation was decided. After the initial week of dose titration 
patients were not allowed to use methadone or other opioids in addition to scheduled 
doses. Of course there is a possibility that patients have been taking less methadone 
than agreed or that they on average have used the agreed dose, but with day to day 
variations. It is also possible that they in addition to methadone have used other 
opioids either from the illegal market or remnants from previous opioid treatment. 
Such behaviours would affect serum concentrations, self reported pain intensity and 
HRQoL, performance in neuropsychological tests and possibly QTc times. Data from 
the pharmacological part of the study give indications that some patients have at some 
occasions used other opioids without reporting the intake to the investigators. In a 9 
months trial in outpatients who are encouraged to live normally and with opioid 
administration three or four times a day it is practically impossible to have absolute 
control over the participants’ opioid intake. In theory patients in clinical trials of 
opioids could be followed in the same way as patients receiving methadone in opioid 
maintenance therapy; with frequent urine drug screenings and surveillance of opioid 
intake. Such rigorous follow up would require enormous resources but would more 
importantly put a substantial and unethical burden and stigma on the participating 
patients.
Self reported HRQoL and pain data could possibly be influenced by the conscious or 
unconscious intent of the study participants. This could be a consequence of an “eager 
to please” attitude. It can be speculated that such an effect is greater when the patients 
know that the investigator will look at the questionnaires during the consultation, as 
was the case in this study.  
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Research question 4 
Opioid switching from morphine to methadone in chronic non-malignant pain 
patients with an unacceptable balance between pain control and side effects during 
morphine therapy:
What is the effect on QTc time? 
The data on QTc time following the switch from morphine to methadone indicate that 
this switch causes a small and lasting increase in QTc time. This finding is in 
accordance with several previous reports from other patient populations (Martell et al. 
2003;Maremmani et al. 2005;Martell et al. 2005;Cruciani et al. 2005;Krantz et al. 
2005), even though the literature is not unanimous (Reddy et al. 2004). Results from 
the small patient cohorts studied until now are not able to evaluate the risk of Torsade 
de Pointes arrhythmia, but the observed increase in QTc supports that start of 
methadone may cause a slightly increased risk of arrhythmia.   
Even though the QT time was assessed by an experienced cardiologist, manual 
measurements can never be exact. However, interobserver and intraobserver 
variability for manual assessment of QT time is reported to be low with mean 
variability of 12 (SD 1) and 6 (SD 6) milliseconds respectively (Tran HT et al. 1998). 
In cross sectional studies estimating the prevalence of QTc prolongation the 
prevalence will due to QT dispersion vary depending on which lead is used for 
assessment (Sadanaga et al. 2006). In the present prospective study the same lead was 
used for QT assessment at each occasion, but it can be questioned whether on each 
ECG the longest QT time should have been identified and used in the analyses. 
Diurnal variations in QTc may also affect the results (Harris and Steare 2006), while 
it is not established whether the time from methadone administration to the ECG is 
obtained affects the results. Because all ECGs were obtained at the same time of the 
day, these factors are not believed to affect the results significantly. On the other hand 
this study may have underestimated the true effect from methadone on QT times. 
Kornick et al. have reported an increase in QT times following start of treatment with 
intravenous morphine to cancer patients (Kornick et al. 2003). All patients in our 
study were treated with oral morphine before the start of methadone and hence may 
have a morphine induced increase of the QT times at baseline. Consequently, the true 
effect from methadone on QT time if given to opioid naïve patients may be larger 
than the effect demonstrated in this study.  
Research question 5 
Opioid switching from morphine to methadone in chronic non-malignant pain 
patients with an unacceptable balance between pain control and side effects during 
morphine therapy:
Are methadone serum concentrations stable during long term treatment and are there 
interindividual differences in opioid metabolism?
The results from the pharmacokinetic part of the methadone switch study indicate that 
serum concentrations of methadone and the primary metabolite EDDP are stable 
during long term treatment with stable doses of methadone. This finding oppose the 
hypothesized autoinduction of methadone metabolism during long term therapy 
(Sawe 1986). The results also demonstrate large interindividual differences in 
morphine and methadone metabolism. Surprisingly the results also indicated that 
several patients seem to have taken opioids in addition to prescribed doses before as 
well as after trial entry. This may affect the validity of results in all parts of the study, 
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but equally importantly indicates that the clinician can not trust patients to be taking 
only the prescribed opioid doses.
In contrast to morphine, serum concentration of methadone was not explained by dose 
of oral methadone in this study. This may be a type 2 error due to small sample size, 
but is probably a consequence of the large interindividual variability of methadone 
bioavailability and half times. This is supported by data from opioid maintenance 
therapy which have reported low correlation between methadone dose and steady 
state serum concentration (de Vos et al. 1995), and that methadone dose can only 
explain about half the variability of methadone serum concentration (Eap et al. 1998). 
On the other hand one study on opioid maintenance therapy found a high correlation 
between daily oral methadone doses adjusted for body weight and plasma 
concentrations of methadone, but also this study observed some outliers with 
unexpected serum concentrations (Wolff et al. 1991).
Serum concentrations of all xenobiotics including opioids are dependent on the time 
from administration/exposure to the sample is obtained. Variations are of course 
largest after a single dose, but serum concentrations are variable also in steady state. 
This variability is described by the peak/trough serum concentration ratio; the ratio 
between the highest and lowest serum concentration between two doses. The time 
from dose administration to peak serum concentration is dependent on the speed of 
uptake and distribution while trough values by definition are expected immediately 
before administration of the next dose. Serum concentrations in the methadone switch 
study were assessed at a standardized time of the day; between 1445 and 1530. This 
time of day was chosen because it corresponds with trough values when a drug is 
administered tree times a day (08-16-23). When some patients required methadone to 
be administered four times a day in order to achieve stable pain control, serum 
concentrations can not be considered as trough samples. Because all patients requiring 
four daily administrations had increased to four administrations within two weeks 
from the switch, the long term data form these patients are also standardized relative 
to drug intake in spite of being neither peak nor trough values. Accordingly the 
conclusion that methadone serum concentrations were stable, is valid. However, when 
serum concentrations are related to medicament dose the lack of standardisation could 
affect the validity of the results in the patients taking methadone four times daily. For 
patients in methadone maintenance therapy with once daily dosing the peak/trough 
ratio is approximately two (Hanna et al. 2005) while the ratio is expected to be 
considerably lower when methadone is administered three or four times a day. To 
avoid problems with non-standardised data for estimation of the correlation between 
total daily dose and serum concentration in the patients receiving methadone four 
times daily, they postponed their second dose two hours at the day of the three months 
evaluation. Accordingly the serum concentrations in all patients are trough values 
seven hours after administration when the relationship between total daily dose and 
serum concentrations was assessed. However, all results based on total methadone 
serum concentration need to be interpreted cautiously as levomethadone (the R-
enantiomer) is responsible for the ȝ-opioid receptor mediated analgesic effects of 
methadone (Kristensen et al. 1995). 
Serum concentrations may also have been influenced by metabolic interaction with 
other drugs. Two patients in our study were concomitantly treated with venlafaxine 
which is known to be an inhibitor of CYP3A4 and two patients were treated with 
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amitriptyline which may possibly influence methadone serum concentrations (Ferrari 
et al. 2004). Conclusions regarding the consequences of these possible interactions 
cannot be drawn due the limited number of patients. 
The LC-MS/MS method is sensitive and specific and was validated according to 
appropriate/standard protocols. There is no reason to believe that difficulties with the 
assay in any way have influenced the results. When unexpected/outlying observations 
were made, the back-up samples were analysed. In none of these cases differences 
between the primary and secondary analyses were observed.
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Conclusions
Based on the papers included in this thesis the following answers to the research 
questions can be given: 
HRQoL assessment methodology in CNMP patients:
I. Is the EORTC QLQ-C30 a valid alternative to the SF-36 for assessment of 
HRQoL in CNMP patients?
x The EORTC QLQ-C30 shows overall acceptable psychometric properties in 
CNMP patients.
x EORTC QLQ-C30 is a valid alternative when a more comprehensive 
assessment of symptoms is desired. 
Comparsion of HRQoL scores between patient groups:
II. How is the HRQoL of CNMP patients admitted to MDPC treatment compared to 
the HRQoL of palliative cancer patients? 
x CNMP patients report substantially poorer HRQoL than the general 
population.
x CNMP patients report equally poor or poorer HRQoL in 11 of 15 EORTC 
QLQ-C30 scales compared to palliative cancer patients.  
Opioid switching from morphine to methadone in CNMP patients with an 
unacceptable balance between pain control and side effects during morphine therapy: 
III. What are the effects on pain control, HRQoL, cognitive functioning and patient 
preference? 
x It seems to improve pain control and functioning in some of the patients.  
x The patients preferring methadone for long term treatment reported 
improved pain control, role functioning and physical functioning while no 
improvement in cognitive functioning was observed.   
x All patients meeting the inclusion criteria in the trial in this thesis do not 
benefit from a switch to methadone and the switch poses a risk of serious 
adverse events like sedation. 
IV. What is the effect on QTc time? 
x The switch is associated with a small, lasting and stable increase in QTc 
time in this patient population.  
V. Are methadone serum concentrations stable during long term treatment and are 
there interindividual differences in opioid metabolism?  
x Serum concentrations of methadone and the primary metabolite EDDP are 
stable during long term methadone treatment with minor dose adjustments. 
x Large interindividual differences were observed for serum concentrations 
and ratios between daily total methadone dose and serum concentration.  
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Issues for further research 
Standardisation of symptom assessment 
Guidelines like the IMMPACT recommendations are one important step towards 
standardisation of symptom assessment. However, in spite of validity and acceptable 
psychometric properties today’s instruments are not ideal. When comprehensive 
assessment is desired the burden on the patients is considerable because numerous 
instruments and tests are required. The consequence is that fragile patients are not 
included, drop out or contribute with incomplete data. One possible strategy for future 
assessment tools is computer based intelligent systems which are able to provide a 
valid and accurate description of the patient’s situation from a minimum of questions. 
For reasons of familiarity the same instruments should be applied in research and 
clinical routine. Such instruments should allow assessment of specific symptoms and 
HRQoL as well as screening for psychiatric comorbidity.
Pain, opioids and cognitive functioning 
Impaired cognitive functioning has previously been reported for CNMP patients and 
CNMP patients on opioids. There have been indications that increased pain intensity 
through an arousal effects improves some aspects of cognitive functioning, but this 
does not disrupt the overall picture of impaired performance in neuropsychological 
tests. In the methadone switch study presented in this thesis the included patients 
performed worse in tests of selective attention and working memory than the general 
population. The improved pain control was not accompanied by improved 
performance in the neuropsychological tests. This indicates that there is no simple 
association between pain intensity and cognitive functioning. Whether start of opioids 
affects cognitive functioning in CNMP patients in either direction needs to be 
addressed in prospective comparative studies.  
Choice of opioid, opioid switching and pharmacogenetics 
There is no solid evidence for the superiority of one opioid compared to other 
common first line opioids in terms of efficacy, side effects and need to switch to 
another opioid. Neither is there any documentation for which opioid to choose when 
the first line opioid fails. RCTs addressing these questions are needed both in cancer 
and CNMP patient populations. Most studies on opioid switching have evaluated a 
switch to methadone, but no trials have compared the efficacy and side effect profile 
of methadone to other opioids in this setting. It has recently been presented evidence 
for a genetic predisposition for individual responses to the different opioids. Genetic 
factors seem to influence both the dose required to obtain pain relief and whether 
acceptable pain control is achieved at all. Trials of opioid switching should include 
pharmacogenetics in order to identify genetic factors of clinical importance for opioid 
treatment. The ultimate goal might be that routine genetic testing can help the 
clinician decide which opioid to choose and indicate the appropriate dose.
Several cases of serious adverse events including sedation during and after a switch to 
methadone have been reported. The ideal switching strategy should ensure a rapid 
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improvement in pain control with few side effects and minimal risk of serious adverse 
events like sedation. Studies of serum concentrations give support to some of the 
presented strategies, but it is not yet established which strategy provides the most 
rapid improvement in pain control together with the least risk of serous adverse 
events. RCTs are required to compare the common switching strategies stop and go 
versus the three day switch. It is possible that different strategies should be applied in 
hospitalized patients who can be monitored closely compared to patients switching to 
methadone at home.   
Which chronic non-malignant pain patients benefit from 
multidisciplinary pain clinic treatment 
This thesis has demonstrated that the HRQoL of CNMP patients admitted to MDPC 
treatment is extremely poor. Previously it has been reported that 33 and 40% percent 
of the population experiencing long lasting pain are not satisfied with the 
investigations performed of the received treatment respectively (Eriksen et al. 2003). 
This might be a consequence of limited availability of MDPC treatment, when only 
patients with extremely poor HRQoL are admitted. Clearly everybody with long 
lasting pain can not be evaluated at a MDPC, but research is needed in order to 
determine how large proportion of CNMP patients does benefit from CNMP 
treatment in terms of increased functioning and quality of life. Such studies should 
also aim at evaluating cost-effectiveness.    
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Errata 
1. Paper III: Two patients have not been accounted for in the flow-sheet on the 
second page. These two patients accepted to be included into the study, but 
one patient was hospitalised before start of the study and one patient could not 
participate due to practical reasons.
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Abstract
The EORTC QLQ-C30 health related quality of life (HRQoL) questionnaire was developed for 
use in clinical cancer trials. It has also been applied in studies of patients with chronic non-
malignant pain in spite of non-documented validity. Validation of the EORTC QLQ-C30 in this 
patient population and comparison with the traditional first choice HRQoL instrument in 
chronic non-malignant pain, the SF-36, is therefore required. 286 patients admitted to the 
tertiary line multidisciplinary pain centre at St. Olav University Hospital in Trondheim, 
Norway completed both the EORTC QLQ-C30 and SF-36 at admittance. Correlations between 
EORTC QLQ-C30 and SF-36 measures of the same concept were between 0.70 and 0.81 for all 
five domains covered by both instruments. Internal consistency was below 0.70 for the EORTC 
QLQ-C30 scales physical functioning (0.57), pain (0.68), role functioning (0.43), cognitive 
functioning (0.66) and nausea/vomiting (0.53) as well as the SF-36 scale role emotional 
functioning (0.66). Large floor or ceiling effects were seen for several EORTC QLQ-C30 
scales. While SF-36 addresses no other symptoms than pain and fatigue the EORTC QLQ-C30 
also includes sleep, financial difficulties, nausea/vomiting, dyspnoea, appetite loss, constipation 
and diarrhoea. Even though some EORTC QLQ-C30 scales have unsatisfactory internal 
consistency, EORTC QLQ-C30 like the SF-36 has overall acceptable psychometric properties. 
The EORTC QLQ-C30 is a valid alternative to the SF-36 when a broader assessment of 
symptoms is desired. 
Keywords: Quality of Life, SF-36, EORTC QLQ-C30, chronic pain, validation 
Running title: EORTC QLQ-C30 and SF-36 in chronic pain
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Introduction 
During the last two decades the concept of Health Related Quality of Life (HRQoL) has 
become increasingly important in clinical medicine as well as medical research. This is 
particularly the case in chronic diseases and in patients with a limited life expectancy. 
Instruments used for the assessment of HRQoL need to be validated in order to ensure that they 
measure what they are intended to, detect true changes over time and differentiate between 
subjects.
HRQoL questionnaires are divided into generic and disease specific instruments. The Medical 
Outcome Study Short Form 36 (SF-36) questionnaire is a generic instrument which has been 
widely used for assessment of HRQoL in studies on chronic pain1,2,3,4 as well as in other 
diseases. The use of parts of this questionnaire is recommended in the IMMPACT 
recommendations for pain clinical trials.5 The European Organization for Research and 
Treatment of Cancer Quality of Life core questionnaire (EORTC QLQ-C30) is a disease 
specific instrument which has been the instrument of choice in cancer trials in Europe.6 The 
two instruments are quite similar and have five domains in common; physical functioning, 
mental health/emotional functioning, social functioning, vitality/fatigue and pain. 
While several pain clinics have used SF-36 in pain clinical trials and clinical routine, others 
have used EORTC QLQ-C30.7,8 While the SF-36 was developed for use in general populations 
and across disease groups, the EORTC QLQ-C30 was developed and validated for use in 
clinical cancer trials. Accordingly the use of EORTC QLQ-C30 in patients with chronic non-
malignant pain can be criticized due to lack of documented validity in this patient population. 
When SF-36 and EORTC QLQ-C30 have previously been compared in cancer populations 
both instruments displayed satisfactory psychometric properties and correlation between the 
five domains covered by both instruments ranged from 0.50 to 0.74.9,10 The instruments have, 
however, not been compared in chronic non-malignant pain patients. 
The objective of this study was to validate the EORTC QLQ-C30 for use in patients with 
chronic non-malignant pain and to compare it with the SF-36 in this patient population. The 
validation of EORTC QLQ-C30 included testing of discrimination, internal consistency, 
sensitivity and construct validity. Furthermore external convergent validity was measured by 
assessing how SF-36 and EORTC QLQ-C30 measures of the same concept correlate with each 
other.
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Material and methods
Patients
From September 1999 to January 2002 all consecutive out-patients admitted to the 
multidisciplinary pain centre at St. Olav University Hospital in Trondheim, Norway completed 
the two HRQoL questionnaires EORTC QLQ-C30 and SF-36 immediately before their first 
consultation as a part of the routine evaluation. Patients with malignant disease or 
acute/subacute pain lasting less than six months were excluded from this study.  
EORTC QLQ-C30
EORTC QLQ-C30 is a cancer-specific 30-item HRQoL questionnaire.11 It consists of 30 
questions. 24 questions form nine multi-item scales presenting various aspects of HRQoL 
while the remaining six are single-item scales describing different cancer relevant symptoms. 
During the scoring procedure raw EORTC QLQ-C30 scores are linearly transformed into 0-100 
scales. For global health status and the five functioning scales a score of 100 corresponds to a 
high HRQoL. For financial difficulties and the eight symptoms a score of 100 implies 
maximum difficulty or symptom burden. Norm-data for the EORTC QLQ-C30 scores of the 
general Norwegian population exists along with other countries.12,13
SF-36
SF-36 consists of 36 questions which form 8 multi-item scales.14 In all scales a score of 100 
corresponds to a high level of functioning or less symptomatology. SF-36 norm data exist for 
the Norwegian general population.15
Data collection 
The HRQoL questionnaires were completed using the computer programme Painscreen and 
data were entered by means of a touch-screen. Painscreen was developed by Janssen Cilag for 
use in Scandinavian pain centres. The questions were asked in the same order as on the paper 
version of the questionnaire. It was not possible to go on to the next question before an answer 
was given. Accordingly there are no missing data in the questionnaires. The two instruments 
were always presented in the same order with EORTC QLQ-C30 as the first and SF-36 as the 
last instrument.
Analysis strategies and statistics 
Descriptive data are presented with means, SDs, medians, ranges and proportions as 
appropriate.
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Discrimination
If discrimination is high, the patients’ responses are distributed along the whole range of 
response alternatives. In a tool with poor discrimination, a large proportion of responses will be 
one of the extreme alternatives. Discrimination is measured by the floor and ceiling effect, 
which is the percentage of responses in either end of the response range.
Reliability
Reliability expressed as internal consistency, is a measure of how well the items in a multi-item 
scale interrelate. This is usually assessed by computing Cronbach’s coefficient (Cronbach’s 
alpha). The score reflects both the number of items and the degree of correlation between 
items. Values above 0.70 usually indicate acceptable internal consistency.  
Sensitivity
The sensitivity measures how well the instrument identifies differences between groups. An 
instrument with a high sensitivity is able to detect a relatively small difference with a modest 
sample size. Sensitivity is measured by comparing the scores of different groups of patients. In 
this study the patient population was divided into seven broad groups according to ICD-10 pain 
diagnosis. Based on clinical experience, significant differences between these patient groups 
were expected. 
Convergence between instruments 
Convergence between instruments (external convergent validity) is an assessment of the 
correlation between SF-36 and EORTC QLQ-C30 measures of the same concept. This is 
included in the multi trait multi method (MTMM) analysis where Pearson’s correlations are 
used to compute the degree of correlation. External convergent validity was assessed for 
physical functioning, social functioning, emotional functioning/mental health, fatigue/vitality 
and pain. A correlation above 0.70 between scales measuring the same concept is considered to 
be an indication of the same underlying concept.16
Construct validity
Construct validation evaluates how well an instrument measures the construct it is intended to 
measure. Construct validity is often divided into convergent and discriminant validity as well 
as comparison of deviation from norm-data.  
When assessing convergent validity one assumes that scales related to the same underlying 
construct show high correlations. Previously correlations above 0.40 have been considered 
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satisfactory for convergent validity.16 However, if correlation is too high (>0.70) it can be 
questioned whether the scales really measure different concepts16 and whether the application 
of two highly correlated scales adds useful information compared to if only one of the scales is 
included. On the opposite, by discriminate validity one assumes that scales measuring different 
constructs should show low correlation, which means well below 0.40. Convergent and 
discriminant validity is assessed in a MTMM analysis. In the MTMM analysis correlations 
between the results from different measurement methods of different traits are presented. In the 
present analyses the HRQoL scales are traits and the two different instruments are methods.  
As part of the construct validation deviations from the age and gender adjusted norm data for 
the two instruments were compared for the five domains covered by both instruments. If 
similar scales or items in the two instruments deviate approximately similarly from the norm, 
one assumes equality between instruments.  
Ethics
The data were collected for clinical purposes as part of the routine evaluation of new patients at 
the multidisciplinary pain centre. The secretary of the Regional Committee for Medical 
Research Ethics approved the use of these data for research without obtaining informed 
consent.
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Results
Patient characteristics 
Out of 602 patients with chronic non-malignant pain admitted during the study period, 286 
(48%) had completed both EORTC QLQ-C30 and SF-36 and were included in the analyses. 
Causes of missing or incomplete HRQoL data were that some days the computer was not 
available or there were technical difficulties, some patients did not have time to complete the 
questionnaire, some were unable due to poor health and some refused. The distribution 
between these causes is not known. The study population included 113 (39%) males and 173 
(61%) females. Mean age was 45 (SD 13) years. The included patients were divided into 7 
groups according to ICD-10 diagnoses; generalised pain conditions (16 %), neck pain (15 %), 
lumbar/thoracic pain (19 %), localised musculoskeletal pain (11 %), neuropathic pain (16 %), 
somatoform pain disorders (9 %) and other pain conditions (14 %). Mean EORTC QLQ-C30 
and SF-36 scores of the patients in the study and standard deviations are presented in table 1 
together with age- and gender adjusted norm-data. Table 2 provides a detailed overview of the 
ICD-10 diagnoses included in each diagnostic group and the number of patients with each ICD-
10 diagnosis. 
Discrimination
Floor and ceiling effects are presented in table 1. Floor effects of 15 and 20% respectively were 
seen for the EORTC QLQ-C30 scales social functioning and role functioning while floor 
effects of 38 to 61% were seen for the EORTC QLQ-C30 single items nausea/vomiting, 
dyspnoea, appetite loss, constipation, diarrhoea and financial difficulties. For the SF-36 scales 
role physical functioning and role emotional functioning floor effects were 69 and 33 
respectively. Ceiling effects were respectively 23, 22 and 42% for the EORTC QLQ-C30 
scales role functioning, cognitive functioning and pain. The EORTC QLQ-C30 single items 
insomnia and financial difficulties had ceiling effects of 21 and 25 while the SF-36 scale role 
emotional functioning had a 19% ceiling effect.  
Internal consistency 
Cronbach’s alpha is computed for all multi item scales and the values are presented in table 1. 
Values below 0.70 are observed for the EORTC QLQ-C30 scales physical functioning (0.57), 
pain (0.68), role functioning (0.43), cognitive functioning (0.66) and nausea/vomiting (0.53) 
and the SF-36 scale role emotional functioning (0.66). The values for the remaining four 
EORTC QLQ-C30 multi item scales and seven SF-36 scales exceeded 0.70.  
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The scores of the seven groups of patients are compared using one-way ANOVA, and results 
are presented in table 3. Both instruments detected significant differences between the groups 
in the physical functioning scale. EORTC QLQ-C30 also detected differences between the 
groups in social functioning, but such difference was not detected by the SF-36. Neither SF-36 
nor EORTC QLQ-C30 separated the groups in the emotional functioning/mental health, 
pain/bodily pain and fatigue/vitality scales.
Convergence between instruments 
For all five domains covered by both instruments, coefficients for external convergent validity 
met the 0.70 criteria, with values ranging from 0.70 to 0.81 (table 4). These values were as they 
should, well above correlation values between the different scales in each instrument (0.15-
0.57). In all cases the correlation between the corresponding scales in the two instruments was 
higher than correlations between the scale in one instrument and the four non-corresponding 
scales in the other instrument.  
Construct validity 
In the MTMM correlation matrix in table 4 the five domains covered by both HRQoL 
instruments are included. With two exceptions similar patterns of the magnitude of correlations 
were found for the two instruments. The exceptions were observed for correlation between 
physical functioning and mental health/emotional functioning and pain/bodily pain. Correlation 
between EORTC QLQ-C30 physical functioning and emotional functioning was 0.15 
compared to a correlation of 0.37 between SF-36 physical functioning and mental health. 
Between physical functioning and pain/bodily pain a value of 0.39 was observed for EORTC 
QLQ-C30 compared to 0.52 for SF-36. 
As part of the construct validation the deviations from norm-data for the five corresponding 
domains were compared. For emotional functioning/mental health, social functioning, 
vitality/fatigue and pain/bodily pain the differences in deviations were 11 or less while the 
difference in physical functioning was 18. 
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Sensitivity
Discussion
In this study the Norwegian translations of both the EORTC QLQ-C30 and SF-36 HRQoL 
questionnaires demonstrated acceptable psychometric properties in patients with chronic non-
malignant pain. However, both instruments have advantages and weaknesses which will be 
discussed below.
Discrimination was good with small or moderate floor and ceiling effects in all QLQ-C30 
functioning scales, but seems to be poor in several symptom scales, particularly the single item 
scales. For the symptoms nausea/vomiting, dyspnoea, appetite loss, diarrhoea and constipation 
floor effects of 43 to 61% were seen together with ceiling effects of 0.3 to 6.6%. This could 
indicate poor ability to differentiate between no symptoms and mild symptoms, but based on 
clinical experience it is probably at least partly a consequence of low prevalence of these 
symptoms in this patient population. In the QLQ-C30 scales role functioning, insomnia and 
financial difficulties floor effects of 13 to 38% were seen together with ceiling effects of 21 to 
26%. For insomnia and financial difficulties this is probably a consequence of the narrow 
response range with only 4 response alternatives. For role functioning this distribution indicates 
that contrary to the other functioning scales, a large part of patients with chronic non-malignant 
pain experience either very poor or excellent role functioning.
For SF-36 the internal consistency was acceptable for all scales while three EORTC QLQ-C30 
scales had values substantially below the 0.70 limit. The Chronbach’s alpha of 0.57 for 
EORTC QLQ-C30 physical functioning is probably a consequence of the narrow range of 
responses when all questions are dichotomous (yes/no). In the last version of the questionnaire, 
this problem is probably reduced because there are currently four response alternatives. For the 
other scales with low internal consistency there are no obvious explanations. In cancer patients 
the EORTC QLQ-C30 internal consistency in multi item scales has been reported to be equal to 
SF-36 values.9,10 The Chronbach’s apha values in these comparative studies are similar to 
findings in other EORTC QLQ-C30 validation studies.16 The poorer Chronbach’s alpha values 
observed in our study indicate that EORTC QLQ-C30 internal consistency is higher in cancer 
patients than in patients with chronic non-malignant pain for physical functioning, role 
functioning and nausea/vomiting. There is no obvious explanation for these differences in 
internal consistency between the two patient populations but it is possible to speculate on 
possible reasons. A possible explanation is that chronic pain affects more specific functional 
areas compared to advanced cancer disease. For instance would localised pain conditions be 
expected to have a strong influence on some functions but less on others. This could be an 
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explanation for the lower correlation between the items in multi item functioning scales in this 
population.
Our results indicate that the sensitivities of the two instruments are about equal. In three 
dimensions neither of the two instruments detected differences between the seven diagnostic 
groups. In physical functioning both instruments detected differences while in social 
functioning only EORTC QLQ-C30 detected differences. It is not established whether different 
chronic pain conditions affect HRQoL data differently. Accordingly our results are either a 
consequence of poor sensitivity for both instruments or illustrate that very different chronic 
pain conditions have similar impact on HRQoL.  
When SF-36 and EORTC QLQ-C30 were previously compared in cancer patients external 
convergent validity correlation values from 0.52 to 0.69 and from 0.50 to 0.74 were seen in two 
different studies.9,10 This is well below values ranging from 0.70 to 0.81 in our study. In spite 
of these differences the overall picture from both populations is that correlation between 
measures of the same concept is high. However, the finding that no correlation values are close 
to 1.0, indicates some differences in content between the instruments.  
When correlation coefficients between different EORTC QLQ-C30 scales from the present 
study are compared to data from cancer patients,16 the coefficient values differ as much as 0.30. 
The largest difference is seen for the correlation between emotional and physical functioning 
with a correlation coefficient of 0.46 in cancer patients compared to 0.15 in patients with 
chronic non-malignant pain. Lower correlations in patients with chronic non-malignant pain 
compared to cancer patients were also seen between pain and physical and emotional 
functioning and between fatigue and physical functioning. A possible interpretation of this 
finding is that the levels of pain and fatigue are of less importance for the level of physical 
functioning, and that the level of pain is of less importance for emotional functioning in 
patients with chronic non-malignant pain compared to cancer patients. On the other hand the 
association between fatigue and emotional functioning is higher in patients with chronic non-
malignant pain with a correlation coefficient of 0.55 compared to 0.36.  
Differences between the two instruments in correlation between physical functioning and 
mental health/emotional functioning indicate that the contents of the physical functioning 
and/or mental health/emotional functioning scales differ between the two instruments. If the 
content was the same in both instruments for both scales, similar correlation coefficients would 
be expected together with similar deviations from norm data. Mean EORTC QLQ-C30 and SF-
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36 physical functioning scores differ with respectively 31 and 49 from norm data while no 
significant difference in deviation from norm data is seen for emotional functioning/mental 
health. This indicates different contents in the physical functioning scales. While the SF-36 
physical functioning scale consists of ten items, the QLQ-C30 only contains five physical 
functioning items. Most of the SF-36 questions are very specific compared to the wider and 
vaguer questions in the QLQ-C30. While SF-36 addresses problems with walking more than 
one mile EORTC QLQ-C30 asks about a long walk. Another possibly important difference is 
that the EORTC QLQ-C30 uses carrying a suitcase as an example of strenuous activity, while 
the SF-36 has running and participation in sport activities as examples of strenuous activity.  
Unfortunately the two HRQoL instruments were only completed by 48% of patients admitted 
to the multidisciplinary pain centre during the study period. This could obviously have caused a 
selection bias in the study and reduce the external validity of the results. While we believe that 
technical difficulties and lack of time would exclude random patients and thus not introduce a 
selection bias, poor health and refusal is probably more likely in patients with poor HRQoL 
scores. As a selection bias can not be disproved the results from the present study should be 
confirmed in future studies.  
The EORTC QLQ-C30 does in spite of unsatisfactory internal consistency in three scales show 
overall acceptable psychometric properties in patients with chronic non-malignant pain. An 
advantage of the EORTC QLQ-C30 compared to the SF-36 is that cognitive functioning and a 
broader spectrum of symptoms are addressed. SF-36 only addresses pain and fatigue while the 
EORTC QLQ-C30 also addresses difficulties of sleep, financial difficulties, nausea/vomiting, 
dyspnoea, appetite loss, constipation and diarrhoea. Some of these symptoms have a low 
prevalence in this patient population, but insomnia and financial difficulties are frequent 
complaints and should be addressed. In this study the high prevalence of difficulties of sleep 
and financial difficulties is reflected in the large ceiling effects and mean deviations from norm 
data. Nausea/vomiting and constipation, on the other hand, are of minor relevance for the 
majority of patients with chronic non-malignant pain, but are frequent side effects for the 
minority who are treated with strong opioids.17 In conclusion the EORTC QLQ-C30 is a valid 
alternative to the SF-36 when a broader assessment of symptoms is desired. The application of 
the EORTC QLQ-C30 may also be desirable to those clinicians who deal with both cancer and 
non-cancer pain patients. In spite of the overall acceptable psychometric properties of both 
instruments the results from the present study indicate that further development of the 
instruments could be required in order to achieve ideal psychometric properties in patients with 
chronic non-malignant pain. 
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Table 1 
EORTC-QLQ-C30 and SF-36 scores and norm data, floor- and ceiling effects and Cronbach’s 
alpha.
Instrument Scale Mean (SD) Norm data* Deviation from norm Floor % Ceiling % 
Cronbach’s 
alpha 
QLQ-C30 Physical functioning 60 (24) 91 -31 1 12 0.57 
Emotional functioning 58 (24) 81 -23 1 4 0.80 
Social functioning  43 (29) 85 -42 15 5 0.75 
Role functioning 52 (33) 93 -41 20 23 0.43 
Cognitive functioning 64 (28) 87 -23 3 22 0.66 
Global Quality of life 36 (19) 73 -37 5 1 0.74 
Pain 82 (19) 21 +61 0 42 0.68 
Nausea/vomiting 12 (18) 4 +8 56 0 0.53 
Fatigue 60 (24) 29 +31 2 9 0.79 
Dyspnoea 29 (30) 13 +16 43 5 Single item 
Insomnia 57 (33) 21 +36 13 26 Single item 
Appetite loss 24 (30) 7 +17 52 5 Single item 
Constipation 22 (31) 11 +11 61 7 Single item 
Diarrhoea 20 (27) 10 +10 56 4 Single item 
Financial difficulties 41 (39) 10 +31 38 21 Single item 
SF-36 Physical functioning 50 (24) 89 -49 1 1 0.89 
Mental health 60 (20) 79 -19 0 1 0.88 
Social functioning 52 (28) 86 -34 6 7 0.84 
Vitality 32 (20) 60 -28 5 0 0.81 
Bodily pain 26 (16) 76 -50 13 1 0.74 
General health 45 (21) 78 -33 0 0 0.70 
Role – physical 13 (24) 81 -68 69 4 0.70 
Role – emotional 40 (36) 84 -44 33 19 0.66 
In EORTC QLQ-C30 functioning scales a high score indicates good functioning/high quality of life. High scores 
in EORTC QLQ-C30 symptom scales indicate worse symptoms/poor quality of life. In all SF-36 scales a high 
score indicates a high quality of life.  
* Age and gender adjusted data from the general Norwegian population (Loge et al and Hjermstad et al). 
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Diagnostic group ICD-10 diagnoses N = %
Generalised pain conditions M79.0 Rheumatism, unspecified (fibromyalgia)  29 10,1
N: 45 (16%) R52.2 Other chronic pain 16 5,6
Neck pain M54.2 Cervicalgia 29 10,1
N: 42 (15%) S13.4 Sprain and strain of cervical spine 13 4,5
Lumbar/thoracic pain M54.4 Lumbago with sciatica 23 8,0
N: 54 (19%) M54.5 Low back pain 27 9,4
M54.6 Pain in thoracic spine 4 1,4
Localised musculoskeletal pain M16.0 Primary coxarthrosis, bilateral 6 2,1
N: 33 (11%) M17.0 Primary gonarthrosis, bilateral 6 2,1
M75.9 Shoulder lesion, unspecified 9 3,1
M79.1 Myalgia 7 2,4
R07.4 Chest pain, unspecified 5 1,7
Neuropathic pain B02.9 Zoster without complication 1 0,3
N: 45 (16%) G35 Multiple sclerosis 1 0,3
G50.1 Atypical facial pain 11 3,8
G54.6 Phantom limb syndrome with pain 1 0,3
G54.8 Other nerve root and plexus disorders 1 0,3
G54.9 Nerve root and plexus disorder, unspecified 1 0,3
G56.8 Other mononeuropathies of upper limb 6 2,1
G57.9 Mononeuropathy of lower limb, unspecified 8 2,8
G58.0 Intercostal neuropathy 4 1,4
G62.9 Polyneuropathy, unspecified 2 0,7
I69.8 Sequelas of other and unspecified cerebrovaskular disease 5 1,7
M89.0 Algoneurodystrophy 4 1,4
Somatoform pain disorders F45.3 Somatoform autonomic dysfunction 14 4,9
N: 25 (9%) F45.4 Persistent somatoform pain disorder 11 3,8
Other pain conditions G43.9 Migraine, unspecified 1 0,3
N: 42 (15%) G44.2 Tension-type headache 7 2,4
M05.9 Seropositive rheumatoid arthritis, unspecified 1 0,3
M54.1 Radiculopathy 10 3,5
R10.2 Pelvic and perineal pain 22 7,7
M76.8 Other enthesopathies of lower limb, excluding foot 1 0,3
Table 2 
Detailed overview of the ICD-10 diagnoses of the included patients.
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Abstract
Methadone is used as an alternative opioid when ﬁrst line opioids fail to provide adequate pain control. Highly variable mor-
phine:methadone dose ratios make switching challenging and little is known about the pharmacokinetics of long lasting methadone
treatment for pain. Twelve patients treated with morphine for chronic non-malignant pain were switched to methadone. Seven of
these patients continued with methadone throughout the nine months study period and only minor dose adjustments were per-
formed. Serum concentrations of morphine, methadone and their metabolites were measured at baseline, day one and two, after
dose titration and one week, ﬁve weeks, three months and nine months after the end of dose titration. Serum concentrations of
methadone and its metabolite EDDP did not change signiﬁcantly from the end of dose titration and during the nine months
(repeated measures ANOVA: p = 0.88 and p = 0.06). Very low correlation between dose ratios and serum concentration ratios
between morphine and methadone was observed. Large interindividual diﬀerences in serum concentrations and metabolism were
observed. Our ﬁndings contradict that autoinduction of methadone metabolism takes place during long term treatment and sup-
ports that a 3-day opioid switch from morphine to methadone followed by a one week titration seems pharmacologically sound.
 2006 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All
rights reserved.
Keywords: Methadone; Morphine; Pharmacokinetic; Chronic pain; Opioid switch
1. Introduction
Morphine is a ﬁrst line opioid in the treatment of
cancer pain (Hanks et al., 2001; Wiﬀen et al., 2003)
and chronic non-malignant pain. Switching to metha-
done is an alternative if morphine does not provide a
satisfactory balance between pain relief and side eﬀects
(de Stoutz et al., 1995; Fredheim et al., 2006a). How-
1090-3801/$32  2006 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights
reserved.
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ever, highly variable morphine:methadone dose ratios
make this switch challenging and little is known about
pharmacokinetic aspects of switching from morphine
to long term methadone treatment. Morphine and
methadone diﬀer in several ways. Oral bioavailability
for morphine is usually 25–35% (Hasselstrom and
Sawe, 1993; Lotsch et al., 1999), but a range from
10% to 43% was reported by Gourlay et al. (1986).
Oral bioavailability for methadone is usually 70–90%,
but values from 40% to 99% are reported (Meresaar
et al., 1981; Gourlay et al., 1986; Dale et al., 2004).
While serum elimination half-time for morphine is 2–
3 h (Sawe, 1986) methadone half-time ranges from 7
to 65 h (Gourlay et al., 1986). Methadone is metabo-
lised to the inactive compound 2-ethylidene-1,5-
dimethyl-3,3-dipenylpyrrolidine (EDDP) via CYP3A4
(Iribarne et al., 1996), but also other CYPs may metab-
olise methadone (Garrido and Troconiz, 1999). It has
been suggested that chronic methadone treatment leads
to increased metabolism by autoinduction (Sawe,
1986). Morphine is primarily eliminated by glucuroni-
dation to morpine-3-glucuronide (M3G) and mor-
phine-6-glucuronide (M6G) via UGT2B7 (Coﬀman
et al., 1997), but is also N-demetylated to normorphine
via CYP3A4 and CYP2C8 (Projean et al., 2003).
Changes in opioid and metabolite serum concentra-
tions during and after switching from morphine to
methadone in chronic pain have not previously been
studied. In this study we provide data on serum concen-
trations of methadone and EDDP during long lasting
methadone therapy and explore other pharmacokinetic
characteristics of a switch from morphine to methadone.
2. Material and methods
2.1. Patients
Twelve patients with chronic non-malignant pain
(age >18 years) scheduled to a change in opioid ther-
apy from oral slow release morphine to oral metha-
done were included in the study. Seven of these
preferred to continue with methadone throughout the
nine months study period. Details on the identiﬁcation
and inclusion of the patients as well as the clinical out-
comes from the study are reported previously (Fred-
heim et al., 2006a).
2.2. Design and blood sampling
During a 3-day period the morphine doses were
reduced by one third each day and substituted with a
daily increase of one third of the assumed equianalgesic
methadone dose (Lawlor et al., 1998; Fredheim et al.,
2006a). Dose ratios between morphine and methadone
of four to one and six to one were applied for doses
below and above 200 mg, respectively. After the switch
the patients entered a one week dose-titration period
and were thereafter followed for nine months. Venous
blood for analyses of serum concentration of morphine
and methadone and their metabolites was sampled at
baseline, at day one and two of the switch, at the
end of the dose titration week (one week after the
switch), two weeks after the switch, six weeks after
the switch and three and nine months after the switch.
All samples were drawn between 1445 and 1530 h. For
morphine this equalled seven hours after morning dose,
while it for methadone equalled two or seven hours
after last dose depending on whether methadone was
administered three or four times daily. Samples for
methadone at three months were always drawn seven
hours after last dose. Blood samples were stored at
room temperature between 1 and 2 h before centrifuga-
tion. After centrifugation (3000 rpm, 10 min) serum
was transferred to cryo-tubes and stored at 20 C
until analysis.
2.3. Analysis
Morphine, M3G, M6G, normorphine, methadone
and EDDP were isolated from serum by solid phase
extraction. The extracted samples were then identiﬁed
and analyzed by a validated LC–MS/MS method (Per-
kin-Elmer 200 series HPLC system API 300 triple quad-
rupol mass spectrum). The limit of quantiﬁcation was
1 ng/ml for all analytes. The standard curve range was
1–50 ng/ml for morphine and normorphine, 1–60 ng/
ml for M6G and 1–500 ng/ml for M3G, methadone
and EDDP. The correlation coeﬃcients were all >0.99.
Interday coeﬃcients of variation varied from 0.1% to
7% for the 25%, 50% and 75% levels of the standard
curves.
2.4. Statistics
Mean, range and standard deviation are reported
when appropriate. Simple linear regression was used
when analyzing how total oral opioid doses could
explain opioid serum concentrations and how serum
concentrations of mother compound could explain
serum concentrations of metabolites. Repeated mea-
sures ANOVA was used when testing for changes in
serum concentrations of methadone and EDDP during
follow-up.
2.5. Ethics
The study was conducted according to the principles
of the Helsinki declaration and was approved by the
Regional Committee for Medical Research Ethics,
Health Region Central Norway. Patients were included
after informed, written consent was obtained.
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3. Results
3.1. Patient characteristics
Table 1 characterizes the patients with respect to age,
gender, pain diagnose, morphine dose at baseline and
methadone dose after titration and at nine months.
Details on opioid doses, pain relief, quality of life and
cognitive functioning (Fredheim et al., 2006a), concom-
itant drug treatment and data on the eﬀect on QTc-time
from the switch (Fredheim et al., 2006b) have been
reported previously.
3.2. Methadone and metabolites
Serum concentrations of methadone (Fig. 1) did not
change signiﬁcantly from the end of dose titration and
throughout the study period (repeated measures
ANOVA, p = 0.88). Serum concentrations of metha-
done varied ﬁvefold (range: 114–551 ng/ml). The ratio
between the total daily oral methadone dose and serum
concentration of methadone varied 8-fold (range 0.10:1–
0.79:1). Total daily oral methadone dose at three
months could not explain serum concentrations of meth-
adone (R2 = 0.06, p = 0.61). Serum-concentration of
EDDP (Fig. 1, lower panel) one week after the end of
dose titration varied sixfold (range: 12–69 ng/ml), and
was explained by serum concentration of methadone
(R2 = 0.77, p = 0.004). The serum concentrations of
EDDP were stable from the end of the dose titration
and throughout the study period (p = 0.055). One
patient (E) had decreased his methadone dose from
5 mg · 4 to 2.5 mg · 4 shortly before the nine months
follow-up, and a 40% decrease in methadone serum con-
centration is seen in this patient from three to nine
months.
3.3. Morphine and metabolites
Serum concentrations of morphine and the metabo-
lites M3G, M6G and normorphine at baseline are pre-
sented in Table 1. Morphine serum concentrations at
baseline varied 15-fold, from 3.7 to 52.2 ng/ml (mean
18.1–SD 16.2). The ratio between total daily oral mor-
phine dose and serum concentration of morphine varied
7-fold (range: 5:1–32:1). The total daily oral morphine
dose explained the serum concentration (R2 = 0.75,
p < 0.000). Morphine was completely eliminated in all
patients within one week. Serum concentrations of
M3G and M6G were explained by serum concentrations
of morphine (R2 = 0.790, p < 0.000 and R2 = 0.786,
p < 0.000, respectively). Serum concentrations of nor-
morphine were not explained by morphine serum con-
centrations (R2 = 0.024, p = 0.631).
3.4. Morphine:methadone ratios
The ratios between total daily doses of oral morphine
and methadone varied threefold (range 1.8/1–4.5/1).
The ratios between serum concentrations of morphine
and methadone varied fourfold (range 12.5:1–50:1).
However, no signiﬁcant correlation between the oral
dose ratios and serum concentration ratios was seen
(Pearson correlation, R = 0.52, p = 0.19).
3.5. Other observations and outliers
The pharmacological analyses identiﬁed some outli-
ers and some unexpected observations were made. At
baseline traces of methadone were detected in patients
G, H and J and in patient J also traces of EDDP. In
patient D who did not report use of morphine or
codeine after the switch, morphine-glucuronides in
Table 1
Patient characteristics
ID Gender/age Pain diagnosis Morphine dose
baseline mg/24 h
Baseline serum concentrations Methadone
dose after
titration mg/24 h
Methadone dose
9 months mg/24 hMorphine M6G M3G Normorphine
A M/58 Low back pain 450 36.9 665.6 3722.0 3.5
B M/47 Low back pain,
cox arthrosis
120 3.7 106.5 538.0 14.3 30 35
C F/67 Low back pain 90 10.4 133.4 981.9 1.2 30
D M/41 Low back pain 150 9.0 123.7 605.4 0.0 85 100
E M/64 Central pain 90 16.3 294.0 1017 2.7 20 10
F F/70 Severe osteoporosis 50 3.8 68.9 455.2 0.0
G M/66 Severe osteoporosis 800 52.2 1878.2 11211.8 5.0
H F/77 Low back pain,
radiculopathy
60 4.4 72.5 432.4 1.5
I M/59 Low back pain 90 7.1 171.3 961.2 0.0 30 22.5
J F/60 Post surgery
neuropathy
180 18.9 472.9 2145.6 4.0 80 90
K F/63 Low back pain 200 40.0 538.9 3549.7 5.3 60 60
L M/50 Low back pain 150 14.2 248.7 1745.0 1.9 70 80
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serum were observed at three months. In patient G
M3G/morphine and M6G/morphine ratios of 215 and
36 were observed compared to average ratios of 104
and 19 in the rest of the patients. However, a rapid
decline in serum concentrations of M3G and M6G
was observed when morphine was substituted with
methadone. In patient B the level of normorphine
exceeded twice the levels in other patients while his
serum-concentration of morphine was one of the lowest.
4. Discussion
Novel information is that methadone serum concen-
trations are stable from the end of dose titration and
during long term treatment with stable doses for pain.
Serum concentrations of EDDP, the primary metha-
done metabolite, are also stable, indicating that metha-
done metabolism is not altered during long term
treatment for pain. This ﬁnding contradicts the hypoth-
esis of metabolic tolerance and autoinduction of hepatic
enzymes during long term methadone therapy (Sawe,
1986). Autoinduction has been hypothesized based on
data reporting decreasing serum concentrations during
long-term methadone treatment with stable doses in opi-
oid maintenance treatment (Verebely et al., 1975; Ang-
gard et al., 1975; Holmstrand et al., 1978).
Our ﬁndings may contribute to the understanding of
the interindividual diﬀerences in dose ratios when
switching from morphine to methadone. In contrast to
morphine, serum concentration of methadone was in
this study not explained by dose of oral methadone. This
may be a type 2 error due to small sample size, but is
probably a consequence of the large interindividual var-
iability of methadone bioavailability and half times.
This is supported by data from opioid maintenance ther-
apy which have reported low correlation between meth-
adone dose and steady state serum concentration (de
Vos et al., 1995), and that methadone dose can only
explain about half the variability of methadone serum
concentration (Eap et al., 1998). One study on opioid
maintenance therapy found a high correlation between
daily oral methadone doses adjusted for body weight
and plasma concentrations of methadone, but also
observed some patients with unexpected serum concen-
trations (Wolﬀ et al., 1991).
Furthermore, we observed a low and not statistically
signiﬁcant correlation between morphine:methadone
Fig. 1. Semilogarithmic plot of methadone and EDDP serum concentrations during nine months methadone treatment.
4 Olav Magnus S. Fredheim et al. / European Journal of Pain xxx (2006) xxx–xxx
ARTICLE IN PRESS
Please cite this article in press as: Fredheim OMS et al., Long term methadone for chronic pain: ..., Eur J. Pain (2006),
doi:10.1016/j.ejpain.2006.09.006
dose ratios and morphine:methadone serum concentra-
tion ratios. The important information here is that
patients requiring the highest methadone dose relative
to morphine dose were not the same as the patients with
the highest methadone serum concentration relative to
morphine serum concentration. However, all results
based on total methadone serum concentration need to
be interpreted cautiously as levomethadone (the R-enan-
tiomer) is responsible for the l-opioid receptor mediated
analgesic eﬀects of methadone (Kristensen et al., 1995).
A 15-fold variation of morphine serum concentrations
was observed while variations for methadone were ﬁve-
fold. One of the possible explanations for this is that
some patients have developed a high degree of opioid
tolerance prior to the opioid switch and that cross-toler-
ance between methadone and other opioids is incom-
plete. Serum concentrations may also have been
inﬂuenced by metabolic interaction with other drugs.
Two patients in our study were concomitantly treated
with venlafaxine which is known to be an inhibitor of
CYP3A4 and two patients were treated with amitripty-
line which may possibly inﬂuence methadone serum
concentrations (Ferrari et al., 2004). There were indica-
tions that metabolism of methadone was inhibited in
these patients, but conclusions cannot be drawn due
the limited number of patients.
Measurement of serum concentrations of mother
compound and metabolites may identify patients who
diﬀer signiﬁcantly from the rest, and thus contribute to
the understanding of interindividual variations in opioid
pharmacology. For instance did only 8 of 12 patients
metabolise morphine to normorphine. Moreover, one
subject showed low morphine levels together with high
normorphine levels, which may indicate that a larger
proportion of morphine than usual is metabolised along
this pathway in this subject. Also, very high levels of
morphine glucuronides were observed in one patient,
which was probably due to rapid generation from mor-
phine, as the glucuronides were rapidly eliminated after
terminating morphine.
Finally, the ﬁnding of M3G in one patient at three
months after the switch indicates that this patient has
used codeine or morphine in addition to methadone.
Also the traces of methadone in three patients at base-
line indicate that all chronic non-malignant pain
patients may not adhere strictly to the treatment plan.
In conclusion, our study has indicated that metha-
done serum concentrations and metabolism are stable
during long term treatment for pain and that large inter-
individual diﬀerences in methadone pharmacokinetics
exist. Previously pharmacogenetic studies on morphine
have to some extent explained the diﬀerences in need
for morphine in cancer patients (Klepstad et al., 2005).
Recently it was also reported that the 118A > G muta-
tion in the OPRM1 gene is associated with decreased
eﬀects of levomethadone when assessed with pupillome-
try after a single dose in healthy volunteers (Lotsch
et al., 2006). Future studies will hopefully determine
the contribution of genetic factors to the interindividual
variation of the pharmacology of methadone in patients.
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Abstract
Case reports and retrospective studies suggest that methadone causes an increase in QTc (QT
time corrected for heart rate) time and risk of torsades de pointes arrhythmia. No prospective
studies in pain patients have been conducted, and data on whether a methadone-induced
increase in QTc time persists during long-term treatment have not been reported. Eight
chronic nonmalignant pain patients experiencing insufﬁcient pain control or intolerable side
effects during treatment with oral morphine switched to oral methadone and were included in
this study. Electrocardiograms were obtained at baseline and at follow-up 2 weeks, and 3 and
9 months after the opioid switch. Start of methadone caused a minor but statistically
signiﬁcant increase in QTc time, while ﬂuctuations in QTc during treatment with stable
doses of methadone were neither clinically nor statistically signiﬁcant. We observed no
episodes of arrhythmias. J Pain Symptom Manage 2006;32:180e185.  2006 U.S.
Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
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Introduction
A prolonged interval between the Q-wave
and the end of the T-wave (QT time) at the
electrocardiogram (ECG) is associated with
an increased risk for arrhythmias, particularly
the potentially lethal torsades de pointes
arrhythmia.1 The risk for torsades de pointes
increases with increasing QTc times (QTc rep-
resents the QT time adjusted for heart rate)
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and is clinically signiﬁcant if the QTc time ex-
ceeds 0.50 seconds.1 Several factors may inﬂu-
ence the QTc time, including gender and the
use of drugs such as antiarrhythmics, macro-
lides, clindamycin, antidepressants, and anti-
psychotic drugs. Opioid analgesics are also
shown to inﬂuence the QTc time. Prolonged
QTc times associated with methadone treat-
ment have been described both during high-
dose intravenous methadone administration
to cancer patients and in patients receiving
oral methadone in opioid maintenance pro-
grams.2,3 QTc time increases from opioids
may also be associated with other opioids, as
observed in cancer patients after start of
intravenous morphine.2
To our knowledge, the change in QTc time
caused by opioid switching from oral slow-
release morphine to oral methadone in the
treatment of chronic nonmalignant pain has
not been reported previously. Moreover,
none of the reports of prolonged QT time
have included more than a single ECG after
the start of methadone. Thus, in this hypothe-
sis-generating study, we report QTc times mea-
sured before opioid switching from morphine
to methadone and QTc times measured 2
weeks, and 3 and 9 months after the opioid
switch in patients treated for chronic nonmalig-
nant pain. The primary outcomewas increase in
QTc 2 weeks after the switch to methadone.
Materials and Methods
This study was conducted according to the
principles of the Helsinki Declaration and was
approved by the Regional Committee for Medi-
cal Research Ethics. After obtaining written
informed consent, patients with chronic nonma-
lignant pain (age >18 years) were included. All
patients were scheduled for a change in opioid
treatment from oral slow-release morphine to
oral methadone. The indications for start of
methadone were insufﬁcient pain control and/
or adverse effects during morphine treatment.
All patients were treated by the multidisciplinary
pain clinic at St. Olav University Hospital, Trond-
heim, Norway, and were screened for indications
for an opioid switch to methadone. Twelve pa-
tients were included. Details on the identiﬁcation
and inclusion of patients, as well as clinical out-
comes including patient preference of opioids
and the effects on pain, health related quality of
life, and cognitive functioning, have been re-
ported in a separate publication.4
Opioid Switching
Theopioid switchwas performedby substitut-
ing the morphine dose during a 3-day period
with the estimated equianalgesic dose ofmetha-
done. The morphine dose was decreased by
one-third each day, and substituted with a daily
increase of one-third of the estimated equianal-
gesic total methadone dose. The dose ratio
betweenmorphine andmethadone shows inter-
individual variation and may be dependent on
dose.5,6 Because all patients included in the
study used low doses of morphine, amorphine:-
methadone ratio ranging from 4:1 to 6:1 was
applied. After the switch was completed, the
patients entered a methadone dose-titration
periodofoneweek toachieve anoptimalbalance
between pain control and side effects. Changes
in other medications were not performed.
ECG
A 12-lead ECG was recorded at baseline 4
days before the start of the opioid switching,
and at 2 weeks, and 3 and 9 months after start
of methadone. The QT interval is deﬁned as
the interval between the Q-wave and the end
of the T-wave. Lead II was preferred for mea-
surement of QT time and RR interval. If the
quality of Lead II precluded proper assess-
ment, Lead I was used. The same lead was mea-
sured on the four consecutive ECGs for each
individual patient. The QTc time was com-
puted using Bazetts formula, QTc¼QT/ORR.
The QT times and the RR intervals were mea-
sured by a cardiologist. The ECGs were also
checked for conditions affecting the validity
of the measured QT time.
Statistics
Paired samples t-test (two-sided test) was
used to test for the primary outcome, which
was increase in QTc 2 weeks after the switch
to methadone. The use of the paired t-test
was based on the assumption of QTc times be-
ing normally distributed and is in accordance
with a previous report.2 Long-term change in
QTc was tested with repeated measures
ANOVA on the observations from the three
follow-up consultations. Statistical analyses
were performed using the SPSS version 11.0.
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Results
Patient Characteristics
Twelve patients were switched frommorphine
to methadone. Four patients were switched
back to morphine before the ﬁrst follow-up
ECG was scheduled. The switches back to mor-
phine were not caused by arrhythmias or other
cardiac symptoms. The remaining eight pa-
tients were included in this study. Age, gender,
cause of pain, other medications and serum
concentrations of magnesium, potassium and
calcium at baseline are shown for each patient
in Table 1. One patient was switched back to
oral morphine before the 3-month follow-up
due to profuse sweating, considered to be
a treatment-related adverse effect. Pain scores
on an 11-point numeric rating scale showed
an average decrease of 2.9 (range 1e6) follow-
ing the switch to methadone.
Doses of Morphine and Methadone
Mean oral morphine dose prior to the opi-
oid switch (baseline ECG) was 134 mg/24
hours. Mean oral methadone dose 2 weeks,
and 3 and 9 months after opioid switching
was 51, 56 and 57 mg/24 hours, respectively.
Daily opioid doses at baseline, 2 weeks, and 3
and 9 months for each patient are reported
in Table 1.
Change in QTc Time
The heart rates, QT times, and QTc times
for each patient at baseline, 2 weeks after
switching to methadone and at the 3- and
9-month follow-up are presented in Table 2.
The mean QTc time increased from 0.416 be-
fore start of methadone to 0.436 2 weeks after
start of methadone (mean change¼ 0.020,
95% CI¼ 0.007e0.032, P¼ 0.01). The changes
in the follow-up observations of QTc time were
not statistically signiﬁcant (repeated measures
ANOVA, P¼ 0.90), indicating that duration
of QTc time was not associated with time
from the switch to methadone. At the 9-month
follow-up, the ECG from one patient (AR)
showed a supraventricular tachycardia and
could not be used for comparison of QTc
time. An additional ECG obtained 2 months
later (sinus rhythm) showed a minor increase
in QTc compared to the 3-month follow-up.
At the 9-month follow-up, ECG recordings
from only precordial leads were of satisfactory
quality for assessment of QTc time in patient
NR, and lead V1 was therefore used for mea-
surement. Patient GT presented a right bundle
branch block at the 9-month follow-up. No
QTc times above 0.50 seconds or episodes of
arrhythmia were observed.
Discussion
The observations from this prospective case
series indicate that opioid switching from low
doses of oral slow-release morphine to an equi-
analgesic dose of oral methadone causes
a small but clinically insigniﬁcant increase in
QTc time. Nine months of follow-up brought
novel information indicating that changes in
QTc during long-term methadone treatment
Table 2
QT Time, RR Interval, and QTc in Seconds
Patient
ID
Baseline
2 Weeks
after Opioid Switch
3 Months
after Opioid Switch
9 Months
after Opioid Switch
QT RR QTc QT RR QTc QT RR QTc QT RR QTc
NRa 0.41 0.79 0.46 0.37 0.65 0.46 0.40 1.00 0.40 0.37 0.88 0.39
IY 0.40 0.85 0.43 0.40 0.81 0.44
VI 0.35 0.72 0.41 0.34 0.65 0.42 0.38 0.77 0.43 0.37 0.84 0.40
ON 0.35 0.69 0.42 0.40 0.83 0.44 0.34 0.69 0.41 0.35 0.70 0.42
ARb,c 0.37 0.79 0.42 0.43 0.93 0.45 0.47 0.90 0.49 0.48 0.92 0.50
IO 0.41 0.90 0.43 0.43 0.94 0.44 0.45 0.87 0.48 0.44 0.94 0.45
SG 0.38 1.03 0.37 0.40 0.91 0.42 0.42 1.06 0.41 0.43 1.05 0.42
GTb,d 0.43 1.27 0.38 0.43 1.07 0.42 0.45 1.19 0.41 0.40 0.87 0.43
Mean 0.39 0.88 0.42 0.40 0.85 0.44 0.42 0.93 0.43 0.41 0.89 0.43
SD 0.03 0.19 0.03 0.03 0.15 0.02 0.05 0.17 0.04 0.05 0.11 0.04
aLead V1 was used for measurements at 9-month follow-up.
bLead I was used for measurements of QT time and RR interval.
cSupraventricular tachycardia at 9 months. Data from new ECG 2 months later.
dRight bundle branch block at 9 months.
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are small and neither clinically nor statistically
signiﬁcant in this population. However, for two
patients, we observed QTc increases close to
clinically signiﬁcant levels.
We observed that low-dose oral methadone
for chronic nonmalignant pain in otherwise
healthy patients caused minor increases in
QTc times. This is novel information because
previous reports of increased QTc times associ-
ated with methadone treatment have been
from patients treated with high doses of intra-
venous methadone,2 patients receiving oral
methadone for opioid maintenance ther-
apy,3,7,8 patients with other potential factors
inﬂuencing the QT interval9,10 or ﬁnally, pa-
tients receiving daily doses of more than
600 mg in the treatment of chronic nonmalig-
nant pain.9 A recent cross-sectional study in-
cluding 104 patients receiving long-term
methadone therapy for chronic pain or opioid
maintenance therapy observed a prolongation
of the QTc time in one-third of the patients.
Multivariate analysis performed in this study
indicated that methadone treatment was asso-
ciated with prolonged QTc in males within
one year of initiation of treatment.11 In con-
trast to these ﬁndings, a retrospective study in-
cluding 56 patients receiving low doses of
methadone for cancer pain did not ﬁnd in-
creases in QTc times.12 None of these studies
investigated the time course of QTc time asso-
ciated with methadone treatment. Further-
more, the conﬂicting ﬁndings illustrate that
the additional risk associated with methadone
treatment is not established.
This study may have underestimated the
true effect from methadone on QT times. Kor-
nick et al.2 have reported an increase in QT
times following start of intravenous morphine
in patients with cancer pain. All patients in
our study were treated with oral morphine be-
fore the start of methadone, and hence may
have a morphine-induced increase of the QT
times at baseline. Consequently, the true effect
from methadone on QT time if given to opioid
naı¨ve patients may be larger than the effect
demonstrated in this study. Ideally, QTc should
be determined based on continuous QT read-
ings to allow for possible changes in QTc dur-
ing the day, but such methodology was not
feasible in outpatients at a pain center.
In this study, neither arrhythmia nor cases of
QTc times above 0.50 seconds were observed.
However, it is important to recognize that
observations obtained in a case series of eight
patients cannot exclude that start of oral
low-dose methadone may cause arrhythmias
or clinically signiﬁcant increases in QTc times.
This is especially true for patients with genetic
predisposition or other risk factors, such as hy-
pokalemia, hypomagnesemia, use of diuretics,
bradycardia, congestive heart failure, or con-
comitant treatment with drugs that predispose
to increases of QTc time.1 This relationship be-
tween methadone and risk factors for arrhyth-
mias was supported by case reports in which
at-risk patients developed torsades de pointes
arrhythmia during methadone treatment.7,9,10
Data in the present study indicate that start
of low doses of methadone caused an increase
in QTc, which was not clinically signiﬁcant and
that QTc was stable during follow-up. This
ﬁnding is supported by a previous cross-sec-
tional study of long-lasting methadone treat-
ment, which observed that one-third of
patients had prolonged QTc but did not ob-
serve any correlation between QTc and dura-
tion of treatment.11 However, the risk of
clinically signiﬁcant QTc prolongation has
not yet been determined. Thus, prospective
studies including patients on both high and
low doses of methadone are needed. Until
data from such studies are available, a cautious
clinical practice might include screening
patients for pathological QT intervals and
known risk factors for long QT syndrome be-
fore initiating methadone treatment and
before and after escalation to high-dose treat-
ment.13 If risk factors are present, the possible
clinical beneﬁt should be carefully balanced
against the possible risk of arrhythmia.
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